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ABSTRACT 49 
 50 
Proteome and transcriptome analyses aim at comprehending the molecular profiles of the 51 
brain, its cell-types and subcellular compartments including myelin. Despite the relevance of 52 
the peripheral nervous system for normal sensory and motor capabilities, analogous 53 
approaches to peripheral nerves and peripheral myelin have fallen behind evolving technical 54 
standards. Here we assess the peripheral myelin proteome by gel-free, label-free mass-55 
spectrometry for deep quantitative coverage. Integration with RNA-Sequencing-based 56 
developmental mRNA-abundance profiles and neuropathy disease genes illustrates the utility 57 
of this resource. Notably, the periaxin-deficient mouse model of the neuropathy Charcot-58 
Marie-Tooth 4F displays a highly pathological myelin proteome profile, exemplified by the 59 
discovery of reduced levels of the monocarboxylate transporter MCT1/SLC16A1 as a novel 60 
facet of the neuropathology. This work provides the most comprehensive proteome resource 61 
thus far to approach development, function and pathology of peripheral myelin, and a 62 
straightforward, accurate and sensitive workflow to address myelin diversity in health and 63 
disease.  64 
 65 
66 
INTRODUCTION 67 
 68 
The ensheathment of axons with myelin enables rapid impulse propagation, a prerequisite 69 
for normal motor and sensory capabilities of vertebrates (1,2). This is illustrated by 70 
demyelinating neuropathies of the Charcot-Marie-Tooth (CMT) spectrum, in which mutations 71 
affecting myelin genes as MPZ, PMP22, GJB1 and PRX impair myelin integrity and reduce 72 
the velocity of nerve conduction in the peripheral nervous system (PNS) (3). 73 
Developmentally, myelination by Schwann cells in peripheral nerves is regulated by axonal 74 
neuregulin-1 (4,5) and the basal lamina (6±8) that is molecularly linked to the abaxonal 75 
Schwann cell membrane via integrins and the dystroglycan complex (9±12). In adulthood, 76 
the basal lamina continues to enclose all axon/myelin-units (13), probably to maintain myelin. 77 
Beyond regulation by extracellular cues, myelination involves multiple proteins mediating 78 
radial sorting of axons out of Remak bundles, myelin membrane growth and layer 79 
compaction (14±18). For example, the Ig-domain containing myelin protein zero (MPZ; also 80 
termed P0) mediates adhesion between adjacent extracellular membrane surfaces in 81 
compact myelin (19). At their intracellular surfaces, myelin membranes are compacted by the 82 
cytosolic domain of MPZ/P0 together with myelin basic protein (MBP; previously termed P1) 83 
(20,21). Not surprisingly, MPZ/P0 and MBP were early identified as the most abundant 84 
peripheral myelin proteins (22,23).  85 
 86 
A system of cytoplasmic channels through the otherwise compacted myelin sheath remains 87 
non-compacted throughout life, i.e. the adaxonal myelin layer, paranodal loops, Schmidt-88 
Lanterman incisures (SLI), and abaxonal longitudinal and transverse bands of cytoplasm 89 
termed bands of Cajal (14,24,25). Non-compacted myelin comprises cytoplasm, cytoskeletal 90 
elements, vesicles and lipid-modifying enzymes, and thus numerous proteins involved in 91 
maintaining the myelin sheath. The cytosolic channels probably also represent transport 92 
routes toward Schwann cell-dependent metabolic support of myelinated axons (26±31).  93 
 94 
Considering that Schwann cells constitute a major proportion of the cells in the PNS, 95 
oligonucleotide microarray analyses have been used for mRNA abundance profiling of total 96 
sciatic nerves (32,33). Indeed, these systematic approaches allowed the identification of 97 
novel myelin constituents including non-compact myelin-associated protein (NCMAP/MP11) 98 
(34). Notwithstanding that the number of known peripheral myelin proteins has grown in 99 
recent years, a comprehensive molecular inventory has been difficult to achieve because 100 
applications of s\stematic (µomics¶) approaches specificall\ to Schwann cells and peripheral 101 
myelin remained comparatively scarce, different from studies addressing oligodendrocytes 102 
and CNS myelin (35±40). One main reason may be that the available techniques were not 103 
sufficiently straightforward for general application. For example, the protein composition of 104 
peripheral myelin was previously assessed by proteome analysis (41). However, at that time 105 
the workflow of sample preparation and data acquisition (schematically depicted in Figure 106 
1A) was very labor-intense and required a substantial amount of input material; yet the depth 107 
of the resulting datasets remained limited. In particular, differential myelin proteome analysis 108 
by 2-dimensional fluorescence intensity gel electrophoresis (2D-DIGE) requires considerable 109 
hands-on-time and technical expertise (41,42). While this method is powerful for the 110 
separation of proteoforms (43), it typically suffers from under-representation of highly basic 111 
and transmembrane proteins. It thus allows comparing the abundance of only few myelin 112 
proteins rather than quantitatively covering the entire myelin proteome. Because of these 113 
limitations and an only modest sample-to-sample reproducibility, 2D-DIGE analysis of myelin, 114 
although unbiased, has not been commonly applied beyond specialized laboratories.  115 
 116 
The aim of the present study was to establish a straightforward and readily applicable 117 
workflow to facilitate both comprehensive knowledge about the protein composition of 118 
peripheral myelin and systematic assessment of differences between two states, e.g., 119 
pathological alterations in a neuropathy model. The major prerequisites were the biochemical 120 
purification of myelin, its solubilization with the detergent ASB-14 and the subsequent 121 
automated digestion with trypsin during filter-aided sample preparation (FASP). The tryptic 122 
peptides were fractionated by liquid chromatography and analyzed by mass spectrometry for 123 
gel-free, label-free quantitative proteome analysis. More specifically, we used nano-flow 124 
ultra-performance liquid chromatography (nanoUPLC) coupled to an electrospray-ionization 125 
quadrupole time-of-flight (ESI-QTOF) mass spectrometer with ion mobility option, providing 126 
an orthogonal dimension of peptide separation. The utilized data-independent acquisition 127 
(DIA) strategy relies on collecting data in an alternating low and elevated energy mode 128 
(MSE); it enables simultaneous sequencing and quantification of all peptides entering the 129 
mass spectrometer without prior precursor selection (reviewed in (44,45)). With their high-130 
duty cycle utilized for the acquisition of precursor ions, MSE-type methods are ideally suited 131 
to reliably quantify proteins based on peptide intensities. Notably, these methods do not 132 
involve the use of spectral libraries in the identification of proteins, different from other DIA 133 
strategies. Instead, the achieved high-complexity fragmentation spectra are deconvoluted 134 
before submission to dedicated search engines for peptide and protein identification (46,47). 135 
In the MSE mode, this deconvolution involves precursor-fragment ion alignment solely on the 136 
basis of chromatographic elution profiles; on top, drift times of ion mobility-separated 137 
precursors are used in the high-definition (HD)MSE mode. An expansion of the latter referred 138 
to as the ultra-definition (UD)MSE mode, additionally implements drift time-dependent 139 
collision energy profiles for more effective precursor fragmentation (48,49).  140 
 141 
Indeed, compared to the previously used manual handling and in-gel digestion, the current 142 
workflow (schematically depicted in Figure 1A) is considerably less labor-intense, and 143 
automated FASP increases sample-to-sample reproducibility. Moreover, differential analysis 144 
by quantitative mass spectrometry (MS) facilitates reproducible quantification of hundreds 145 
rather than a few distinct myelin proteins. Together, the present workflow increases the 146 
efficacy of assessing the peripheral myelin proteome while shifting the main workload from 147 
manual sample preparation and gel-separation to automated acquisition and processing of 148 
data. We propose that comprehending the expression profiles of all myelin proteins in the 149 
healthy PNS and in myelin-related disorders can contribute to advancing our understanding 150 
of the physiology and pathophysiology of peripheral nerves.  151 
152 
RESULTS 153 
 154 
Purification of peripheral myelin  155 
We biochemically enriched myelin as a light-weight membrane fraction from pools of sciatic 156 
nerves dissected from mice at postnatal day 21 (P21) using an established protocol of 157 
discontinuous sucrose density gradient centrifugation (41,50), in which myelin membranes 158 
accumulate at the interface between 0.29 and 0.85 M sucrose. By immunoblotting, proteins 159 
specific for both compact (MPZ/P0, MBP, PMP2) and non-compact (PRX) myelin were 160 
substantially enriched in the myelin fraction compared to nerve lysates (Figure 1B). 161 
Conversely, axonal (NEFH, KCNA1) and mitochondrial (VDAC) proteins and a marker for the 162 
Schwann cell nucleus (KROX20/EGR2) were strongly reduced in purified myelin. Together, 163 
these results imply that biochemically purified peripheral myelin is suitable for systematic 164 
analysis of its protein composition. 165 
 166 
Proteome analysis of peripheral myelin 167 
It has long been difficult to accurately quantify the most abundant myelin proteins both in the 168 
CNS (PLP, MBP, CNP (51)) and the PNS (MPZ/P0, MBP, PRX; this work), probably owing to 169 
their exceptionally high relative abundance. For example, the major CNS myelin constituents 170 
PLP, MBP and CNP comprise 17, 8 and 4% of the total myelin protein, respectively (51). We 171 
have recently provided proof of principle (52) that the mass spectrometric quantification of 172 
these high-abundant myelin proteins is accurate and precise when data are acquired in the 173 
MSE data acquisition mode and proteins are quantified according to the TOP3 method, i.e. if 174 
their abundance values are obtained based on the proven correlation between the average 175 
intensity of the three peptides exhibiting the most intense mass spectrometry response and 176 
the absolute amount of their source protein (53,54). Using data acquisition by MSE we 177 
confirmed that CNP constitutes about 4% of the total CNS myelin proteome and that the 178 
abundance of CNP in myelin from mice heterozygous for the Cnp gene (CnpWT/null) compared 179 
to wild-type mice is 50.7% (r0.4%), in agreement with the halved gene dosage and gel-180 
based quantification by silver staining or immunoblotting (52).  181 
 182 
When applying the MSE mode to PNS myelin, we quantified 351 proteins with a false 183 
discovery rate (FDR) of <1% at peptide and protein level and an average sequence coverage 184 
of 35.5% (Figure 1-source data 1). While MSE (labeled in orange in Figure 1C) indeed 185 
provided a dynamic range of more than four orders of magnitude and thus quantitatively 186 
covered the exceptionally abundant myelin proteins MPZ/P0, MBP and PRX, the number of 187 
quantified proteins appeared limited when spectral complexity was deconvoluted solely on 188 
the basis of chromatographic elution profiles. Accordingly, by using the UDMSE mode, which 189 
comprises ion mobility for additional peptide separation as well as drift time-specific collision 190 
energies for peptide fragmentation, proteome coverage was increased about three-fold (1078 191 
proteins quantified; average sequence coverage 34.3%; Figure 1-source data 1). However, 192 
the dynamic range of UDMSE (labeled in blue in Figure 1C) was found to be somewhat 193 
compressed compared to that of MSE, which can be considered an expectable feature of 194 
traveling wave ion mobility devices (55), where the analysis of pulsed ion packages leads to 195 
a temporal and spatial binning of peptides during ion mobility separation. Indeed, this 196 
manifests as a ceiling effect for the detection of exceptionally intense peptide signals, which 197 
results in an underestimation of the relative abundance of MPZ/P0, MBP and PRX by 198 
UDMSE. 199 
 200 
The complementary nature of the MSE and UDMSE data acquisition modes led us to 201 
conclude that a comprehensive analysis of the myelin proteome that facilitates both correct 202 
quantification of the most abundant proteins and deep quantitative coverage of the proteome 203 
would require analyzing the same set of samples with two different instrument settings for 204 
MSE and UDMSE, respectively. Considering that instrument time is a bottleneck for the 205 
routine differential proteome analysis of myelin from mutant mice, we aimed to combine the 206 
strengths of MSE and UDMSE into a single data acquisition mode. Based on a gene ontology 207 
enrichment analysis for cellular components of the 200 proteins of highest and lowest 208 
abundance from the UDMSE dataset, we reali]ed that the µbottomµ of the quantified proteome 209 
is probably largely unrelated to myelin but dominated by contaminants from other subcellular 210 
sources including mitochondria. We thus reasoned that for a myelin-directed data acquisition 211 
mode, proteome depth may be traded in for a gain in dynamic range and devised a novel 212 
method referred to as dynamic range enhancement (DRE)-UDMSE, in which a deflection lens 213 
is used to cycle between full and reduced ion transmission during mass spectrometric 214 
scanning. Indeed, DRE-UDMSE quantified an intermediate number of proteins in PNS myelin 215 
(554 proteins; average sequence coverage 30.6%; Figure 1-source data 1) while providing 216 
an intermediate dynamic range (labeled in green in Figure 1C). We thus consider DRE-217 
UDMSE as the data acquisition mode of choice most suitable for routine differential myelin 218 
proteome profiling (see below). 219 
 220 
Overall, we found a high reproducibility between replicates and even among the different 221 
data acquisition modes as indicated by Pearson¶s correlation coefficients for protein 222 
abundance in the range of 0.765-0.997 (Figure 1-supplement 1). When comparing the 223 
proteins identified in PNS myelin using the three data acquisition modes, we found a very 224 
high overlap (Figure 1D). We also found a high overlap (Figure 1E) between the proteins 225 
identified in the present study by UDMSE and those detected in previous proteomic 226 
approaches to PNS myelin (41,42), thus allowing a high level of confidence. Together, the 227 
three data acquisition modes exhibit distinct strengths in the efficient quantification of 228 
exceptionally abundant proteins (MSE), establishing a comprehensive inventory (UDMSE) 229 
and gel-free, label-free differential analysis of hundreds of distinct proteins (DRE-UDMSE) in 230 
peripheral myelin (see Figure 1A). Yet, analyzing the same set of samples by different 231 
modes may not always be feasible in all routine applications when considering required 232 
instrument time.  233 
 234 
Relative abundance of peripheral myelin proteins 235 
Considering that MSE provides the high dynamic range required for the quantification of the 236 
most abundant myelin proteins, we calculated the relative abundance of the 351 proteins 237 
identified in myelin by MSE (Figure 1-source data 1). According to quantitative assessment 238 
of this dataset, the most abundant PNS myelin protein, myelin protein zero (MPZ/P0), 239 
constitutes 44% (+/-4% relative standard deviation (RSD)) of the total myelin protein (Figure 240 
2). Myelin basic protein (MBP), periaxin (PRX) and tetraspanin-29 (CD9) constitute 18% (+/-241 
1% RSD), 15% (+/-1%) and 1% (+/-0.2%) of the total myelin protein, respectively (Figure 2). 242 
For MPZ/P0 and MBP, our quantification by MSE is in agreement with but specifies prior 243 
estimations upon gel-separation and protein labeling by Sudan-Black, Fast-Green or 244 
Coomassie-Blue, in which they were judged to constitute 45±70% and 2±26% of the total 245 
myelin protein, respectively (22,56±58). However, gel-based estimates of the relative 246 
abundance of myelin proteins were not very precise with respect to many other proteins, 247 
including those of high molecular weight. Indeed, periaxin was identified as a constituent of 248 
peripheral myelin after the advent of gradient SDS-PAGE gels (59), which allowed improved 249 
migration of large proteins into gels. The present MSE-based quantification of myelin proteins 250 
also extends beyond and partially adjusts an earlier mass spectrometric approach (41). 251 
Indeed, the current approach identified and quantified more myelin proteins, probably owing 252 
to improved protein solubilization during sample preparation and higher dynamic range of the 253 
used mass spectrometer. By MSE, known myelin proteins (Table 1) collectively constitute 254 
over 85% of the total myelin protein (Figure 2) while proteins not yet associated with myelin 255 
account for the remaining 15% of the total myelin protein. 256 
 257 
Comprehensive compendium and comparison to the transcriptome 258 
To systematically elucidate the developmental abundance profiles of the transcripts that 259 
encode peripheral myelin proteins (Figure 3), we used our combined proteome inventory of 260 
peripheral myelin (Figure 1-source data 1) to filter mRNA abundance data of all genes 261 
expressed in sciatic nerves. By this strategy, Figure 3 displays only those transcripts of 262 
which the protein product was identified in peripheral myelin rather than all transcripts in the 263 
nerve, thereby discriminating myelin-related mRNAs from other mRNAs such as those 264 
present in peripheral axons, fibroblasts, immune cells etc. In this assessment we additionally 265 
included PMP22 although it was not detected by MS as well as 45 proteins exclusively 266 
identified by LC-MS of myelin separated by SDS-PAGE (Figure 1-source data 1). For 267 
mRNA abundance profiles, we exploited a recently established RNA sequencing analysis 268 
(RNA-Seq; platform Illumina HiSeq 2000) of sciatic nerves dissected form wild type Sprague 269 
Dawley rats at embryonic day 21 (E21), P6, P18 and 6 months (60). RNA-Seq provides 270 
reliable information about the relative abundance of all significantly expressed genes and is 271 
thus not limited to those represented on the previously used oligonucleotide microarrays 272 
(41). The raw data (accessible under GEO accession number GSE115930) were normalized 273 
(Figure 3-source data 1) and standardized. When comparing the proteome and 274 
transcriptome datasets, significant mRNA abundance was detected for all 1046 transcripts 275 
for which an unambiguous unique gene identifier was found (Figure 3). 126 transcripts 276 
displayed developmentally unchanged abundance levels, i.e., abundance changes below a 277 
threshold of 10% coefficient of variation (Figure 3B; Figure 3-source data 1).  278 
 279 
By fuzzy c-means clustering, those 920 transcripts that showed developmental abundance 280 
changes were grouped into 5 clusters (Figure 3A; Figure 3-source data 1). Among those, 281 
one cluster corresponds to an mRNA-abundance peak coinciding with an early phase of 282 
myelin biogenesis (cluster µP6-UPµ), which includes the highest proportion of known myelin 283 
proteins (Table 1) such as MPZ/P0, MBP, PRX, cyclic nucleotide phosphodiesterase (CNP), 284 
fatty acid synthase (FASN), myelin-associated glycoprotein (MAG), proteolipid protein 285 
(PLP/DM20), cell adhesion molecule-4 (CADM4/NECL4), connexin-29 (GJC3), claudin-19 286 
(CLDN19) and CKLF-like MARVEL-transmembrane domain containing protein-5 (CMTM5). 287 
However, many known myelin proteins clustered together according to their mRNA-288 
abundance peak coinciding with a later phase of myelination (cluster µP18-UPµ), including 289 
peripheral myelin protein 2 (PMP2), tetraspanin-29 (CD9), tetraspanin-28 (CD81), connexin-290 
32 (GJB1), plasmolipin (PLLP), junctional adhesion molecule-3 (JAM3), CD59 and 291 
dystrophin-related protein-2 (DRP2). The proportion of known myelin proteins was lower in 292 
the clusters corresponding to mRNA-abundance peaks in adulthood (clusters µlate-UPµ, µU-293 
shapedµ). Yet, a considerable number of transcripts displayed abundance peaks at the 294 
embryonic time-point (cluster µDescendingµ), including carbonic anhydrase 2 (CA2), cofilin-1 295 
CFL1), tubulin beta-4 (TUBB4b) and band 4.1-protein B (EPB41L3). Generalized, the 296 
clusters were roughly similar when comparing previous oligonucleotide microarray analysis 297 
of mouse sciatic nerves (41) and the RNA-Seq analysis of rat sciatic nerves (this study); yet, 298 
the latter provides information on a larger number of genes and with a higher level of 299 
confidence. Together, clustering of mRNA abundance profiles allows categorizing peripheral 300 
myelin proteins into developmentally co-regulated groups.  301 
 302 
When systematically assessing the proteins identified in myelin by gene ontology (GO)-term 303 
analysis, the functional categories over-represented in the entire myelin proteome included 304 
cell adhesion, cytoskeleton and extracellular matrix (labeled in turquoise in Figure 4). When 305 
analyzing the clusters of developmentally co-expressed transcripts (from Figure 3), proteins 306 
associated with the lipid metabolism were particularly enriched in the P6-UP and P18-UP 307 
clusters, while those associated with the extracellular matrix (ECM) were over-represented in 308 
the U-shaped and Descending clusters (Figure 4). For comparison, known myelin proteins 309 
(Table 1) were over-represented in the P6-UP and P18-UP clusters (Figure 4). Together, 310 
our proteome dataset provides comprehensive in-depth coverage of the protein constituents 311 
of peripheral myelin purified from the sciatic nerves of wild type mice, and comparison to the 312 
transcriptome allows identifying developmentally co-regulated and functional groups of 313 
myelin proteins. Our data thus supply a solid resource for the molecular characterization of 314 
myelin and for discovering functionally relevant myelin proteins.  315 
 316 
Neuropathy genes encoding myelin proteins  317 
Heritable neuropathies can be caused by mutations affecting genes preferentially expressed 318 
in neurons, Schwann cells or both (3,61±63). To systematically assess which neuropathy-319 
causing genes encode peripheral myelin proteins, we compared our myelin proteome 320 
dataset with a current overview about disease genes at the NIH National Library of Medicine 321 
at https://ghr.nlm.nih.gov/condition/charcot-marie-tooth-disease#genes. Indeed, 31 myelin 322 
proteins were identified to be encoded by a proven neuropathy gene (Table 2), a 323 
considerable increase compared to eight disease genes found in a similar previous approach 324 
(41). Notably, this increase is owing to both the larger size of the current myelin proteome 325 
dataset (Figure 1E) and the recent discovery of numerous neuropathy genes by the 326 
widespread application of next generation sequencing.  327 
 328 
Pathological proteomic profile of peripheral myelin in a neuropathy model 329 
The results presented thus far were based on analyzing myelin of healthy wild type mice; yet 330 
we also sought to establish a straightforward method to systematically assess myelin 331 
diversity, as exemplified by alterations in a pathological situation. As a model we chose mice 332 
carrying a homozygous deletion of the periaxin gene (Prx-/-) (26,64). Periaxin (PRX) is the 333 
third-most abundant peripheral myelin protein (Figure 2) and scaffolds the dystroglycan 334 
complex in Schwann cells. Prx-/- mice represent an established model of Charcot-Marie-335 
Tooth disease type 4F (65±67). Aiming to assess the myelin proteome, we purified myelin 336 
from pools of sciatic nerves dissected from Prx-/- and control mice at P21. Upon SDS-PAGE 337 
separation and silver staining the band patterns appeared roughly similar (Figure 5A), with 338 
the most obvious exception of the absence of the high-molecular weight band constituted by 339 
periaxin in Prx-/- myelin. Yet, several other bands also displayed genotype-dependent 340 
differences in intensity. As expected, PRX was also undetectable by MSE in Prx-/- myelin, in 341 
which most of the total myelin protein was constituted by MPZ/P0 and MBP (Figure 5B; 342 
Figure 5-source data 1).  343 
 344 
Upon differential analysis by DRE-UDMSE (Figure 5-source data 2), multiple proteins 345 
displayed genotype-dependent differences as visualized in a heatmap displaying those 40 346 
proteins of which the abundance was reduced or increased with the highest statistical 347 
significance in Prx-/- compared to control myelin (Figure 5C). For example, the abundance of 348 
the periaxin-associated dystrophin-related protein 2 (DRP2) was strongly reduced in Prx-/- 349 
myelin, as previously shown by immunoblotting (9). Notably, the abundance of multiple other 350 
proteins was also significantly reduced in Prx-/- myelin, including the extracellular matrix 351 
protein laminin C1 (LAMC1; previously termed LAMB2), the laminin-associated protein 352 
nidogen (NID1), Ig-like cell adhesion molecules (CADM4, MAG), the desmosomal junction 353 
protein desmin (DES), cytoskeletal and cytoskeleton-associated proteins (EPB41L3, MAP1A, 354 
CORO1A, SPTBN1, various microtubular and intermediate filament monomers), the 355 
monocarboxylate transporter MCT1 (also termed SLC16A1) and the MCT1-associated (68) 356 
immunoglobulin superfamily protein basigin (BSG, also termed CD147). On the other hand, 357 
proteins displaying the strongest abundance increase in Prx-/- myelin included immune-358 
related proteins (LGALS3, LYZ2, CTSD), cytoskeletal and cytoskeleton-associated proteins 359 
(CAPG, CORO1C, CNN3, several myosin heavy chain subunits), peroxisomal enzymes 360 
(CAT, HSD17B4, MDH1) and known myelin proteins (PLLP/plasmolipin, CRYAB, 361 
GJB1/CX32). For comparison, the abundance of the marker proteolipid protein (PLP/DM20) 362 
(69) and the periaxin-associated integrin beta-4 (ITGB4) (12) in myelin was unaltered in Prx-/- 363 
myelin. Together, differential proteome analysis finds considerably more proteins and protein 364 
groups to be altered in Prx-/- myelin than previously known (Figure 5C, D-Dµµµ), probably 365 
reflecting the complex pathology observed in this model (26,64). 366 
 367 
The monocarboxylate transporter MCT1/SLC16A1 expressed by myelinating 368 
oligodendrocytes (70,71) and Schwann cells (28,72) has been proposed to supply lactate or 369 
other glucose breakdown products to axons, in which they may serve as substrate for the 370 
mitochondrial production of ATP (73±75). In this respect it was striking to find the abundance 371 
of MCT1 significantly reduced in peripheral myelin when PRX is lacking (Figure 5C), a result 372 
that we were able to confirm by immunoblotting (Figure 5E) and immunolabeling of teased 373 
fiber preparations of sciatic nerves (Figure 5F). Notably, reduced expression of MCT1 in 374 
Slc16a1+/- mice impairs axonal integrity at least in the CNS (70,76). The reduced abundance 375 
of MCT1 thus represents an interesting novel facet of the complex pathology in Prx-/- mice. 376 
Considering that the integrity of peripheral axons may be impaired in Prx-/- mice, we 377 
assessed their quadriceps nerves. Indeed, Prx-/- mice displayed reduced axonal diameters, a 378 
progressively reduced total number of axons and a considerable number of myelin whorls 379 
lacking a visible axon (Figure 6), indicative of impaired axonal integrity (77). Yet we note that 380 
molecular or neuropathological features other than the reduced abundance of MCT1 381 
probably also contribute to the axonopathy in Prx-/- mice.  382 
 383 
Together, gel-free, label free proteome analysis provides a cost- and time-efficient method 384 
that provides an accurate, sensitive tool to gain systematic insight into the protein 385 
composition of healthy peripheral myelin and its alterations in pathological situations. Indeed, 386 
gel-free proteome analysis is particularly powerful and comprehensive compared to 2D-387 
DIGE; the workflow presented here appears readily applicable to other neuropathy models, 388 
thereby promising discovery of relevant novel features of their neuropathology.  389 
 390 
391 
DISCUSSION 392 
 393 
We used gel-free, label-free quantitative mass spectrometry to assess the protein 394 
composition of myelin biochemically purified from the sciatic nerves of wild-type mice, 395 
thereby establishing a straightforward and readily applicable workflow to approach the 396 
peripheral myelin proteome. The key to comprehensiveness was to combine the strengths of 397 
three data acquisition modes, i.e., MSE for correct quantification of high-abundant proteins, 398 
UDMSE for deep quantitative proteome coverage including low-abundant proteins and DRE-399 
UDMSE for differential analysis. We suggest that DRE-UDMSE provides a good compromise 400 
between dynamic range, identification rate and instrument run time for routine differential 401 
myelin proteome profiling as a prerequisite for a molecular understanding of myelin 402 
(patho)biology. We have also integrated the resulting compendium with RNA-Seq-based 403 
mRNA abundance profiles in peripheral nerves and neuropathy disease loci. Beyond 404 
providing the largest peripheral myelin proteome dataset thus far, the workflow is appropriate 405 
to serve as starting point for assessing relevant variations of myelin protein composition, e.g., 406 
in different nerves, ages, species and in pathological conditions. The identification of 407 
numerous pathological alterations of myelin protein composition in the Prx-/- neuropathy 408 
model indicates that the method is well suited to assess such diversity.  409 
 410 
Aiming to understand nervous system function at the molecular level, multiple µomicsµ-scale 411 
projects assess the spatio-temporal expression profiles of all mRNAs and proteins in the 412 
CNS including oligodendrocytes and myelin (35±39). Yet, peripheral nerves are also 413 
essential for normal sensory and motor capabilities. Prior approaches to the molecular 414 
profiles of Schwann cells and PNS myelin thus far, however, were performed >8 years ago 415 
(32±34,41,78±80), and the techniques have considerably advanced since. For example, 416 
current gel-free, label-free mass spectrometry can simultaneously identify and quantify the 417 
vast majority of proteins in a sample, thereby providing comprehensive in depth-information. 418 
Moreover, RNA-Seq technology has overcome limitations of the previously used microarrays 419 
for characterizing mRNA abundance profiles with respect to the number of represented 420 
genes and the suitability of the oligonucleotide probes. The present compendium thus 421 
provides high confidence with respect to the identification of myelin proteins, their relative 422 
abundance and their developmental mRNA expression profiles. This view is supported by the 423 
finding that over 80% of the total myelin proteome is constituted by approximately 50 424 
previously known myelin proteins. We believe that the majority of the other identified proteins 425 
represent low-abundant myelin-associated constituents in line with the high efficiency of 426 
biochemical myelin purification. Doubtless, however, the myelin proteome also comprises 427 
contaminants from other cellular sources, underscoring the need of independent validation 428 
for establishing newly identified constituents as true myelin proteins. 429 
 430 
Do myelin proteins exist that escape identification by standard proteomic approaches? 431 
Indeed, some proteins display atypically distributed lysine and arginine residues, which 432 
represent the cleavage sites of the commonly used protease trypsin. The tryptic digest of 433 
these proteins leads to peptides that are not well suited for chromatographic separation 434 
and/or mass spectrometric detection/sequencing, as exemplified by the small hydrophobic 435 
tetraspan-transmembrane myelin proteins MAL (81) and PMP22 (82). We can thus not 436 
exclude that additional proteins with atypical tryptic digest patterns exist in peripheral myelin, 437 
which would need to be addressed by the use of alternative proteases. Moreover, potent 438 
signaling molecules including erbB receptor tyrosine kinases (83,84) and G-protein coupled 439 
receptors (GPRs) (85±87) display exceptionally low abundance. Such proteins may be 440 
identified when applying less stringent identification criteria, e.g., by requiring the sequencing 441 
of only one unique peptide per protein. However, lower stringency would also result in 442 
identifying false-positive proteins, which we wished to avoid for the purpose of the present 443 
compendium. We note that a truly comprehensive spatio-temporally resolved myelin 444 
proteome should preferentially also include systematic information about protein isoforms 445 
and post-translational modifications, which still poses technical challenges.  446 
 447 
Mutations affecting the periaxin (PRX) gene in humans cause CMT type 4F (65,88±90); the 448 
neuropathology resulting from mutations affecting periaxin has been mainly investigated in 449 
the Prx-/- mouse model. Indeed, Prx-/- mice display a progressive peripheral neuropathy 450 
including axon/myelin-units with abnormal myelin thickness, demyelination, tomaculae, onion 451 
bulbs, reduced nerve conduction velocity (64), reduced abundance and mislocalization of the 452 
periaxin-associated DRP2 (9) and reduced internode length (26). Absence of SLIs (64) and 453 
bands of Cajal (26) imply that the non-compact myelin compartments are impaired when 454 
PRX is lacking. In the differential analysis of myelin purified from Prx-/- and control mice we 455 
find that the previously reported reduced abundance of DRP2 (9) represents one of the 456 
strongest molecular changes in the myelin proteome when PRX is lacking. Notably, the 457 
reported morphological changes in this neuropathy model (9,26,64) go along with alterations 458 
affecting the abundance of multiple other myelin-associated proteins, including junctional, 459 
cytoskeletal, extracellular matrix and immune-related proteins as well as lipid-modifying 460 
enzymes. Thus, the neuropathology in Prx-/- mice at the molecular level is more complex 461 
than previously anticipated. It is striking that the abundance of the monocarboxylate 462 
transporter MCT1/SLC16A1 that may contribute to the metabolic supply of lactate from 463 
myelinating cells to axons (27±31) is strongly reduced in Prx-/- myelin. Considering that 464 
MCT1 in Schwann cells mainly localizes to Schmidt Lanterman incisures (SLI) (28) and that 465 
SLI are largely absent from myelin when PRX is lacking (64), the reduced abundance of 466 
MCT1 in Prx-/- myelin may be a consequence of the impaired myelin ultrastructure. Yet, 467 
considering that SLI are part of the cytosolic channels that may represent transport routes 468 
toward Schwann cell-dependent metabolic support of myelinated axons, the diminishment of 469 
MCT1 may contribute to reduced axonal diameters or axonal loss in Prx-/- mice, probably in 470 
conjunction with other molecular or morphological defects. Together, the in depth-analysis of 471 
proteins altered in neuropathy models can contribute to an improved understanding of nerve 472 
pathophysiology.  473 
 474 
Compared to a previous approach (41), the number of proven neuropathy genes of which the 475 
encoded protein is mass spectrometrically identified in peripheral myelin has increased four-476 
fold from eight to 32 in the present study. This reflects both that the number of proteins 477 
identified in myelin has approximately doubled and that more neuropathy genes are known 478 
due to the common use of genome sequencing. We note that our compendium comprises 479 
not only myelin-associated proteins causing (when mutated) demyelinating CMT1 (e.g., 480 
MPZ/P0, NEFL, PMP2) or intermediate CMT4 (GDAP1, NDRG1, PRX) but also axonal 481 
CMT2 (RAB7, GARS, HSPB1). Yet, the expression of genes causative of CMT2 is not 482 
necessarily limited to neurons, as exemplified by the classical myelin protein MPZ/P0. 483 
Indeed, a subset of MPZ-mutations causes axonal CMT2I or CMT2J (91±95), probably 484 
reflecting impaired axonal integrity as consequence of a mutation primarily affecting 485 
Schwann cells. We also note that the nuclear EGR2/KROX20 causative of demyelinating 486 
CMT1D has not been mass spectrometrically identified in myelin, reflecting that Schwann cell 487 
nuclei are efficiently removed during myelin purification.  488 
 489 
While morphological analysis of peripheral nerves by light and electron microscopy is routine 490 
in numerous laboratories, systematic molecular analysis has been less straightforward. 491 
Using the sciatic nerve as a model, we show that systematic assessment of the myelin 492 
proteome and the total nerve transcriptome are suited to determine comprehensive 493 
molecular profiles in healthy nerves and in myelin-related disorders. Myelin proteome 494 
analysis can thus complement transcriptome analysis in assessing development, function 495 
and pathophysiology of peripheral nerves.  496 
497 
MATERIALS AND METHODS 498 
 499 
Mouse models 500 
Prx-/- mice (64) were kept on c57Bl/6 background in the animal facility of the University of 501 
Edinburgh (United Kingdom). Genotyping was by PCR on genomic DNA using the forward 502 
primers 5µ-CAGATTTGCT CTGCCCAAGT and 5µ-CGCCTTCTAT CGCCTTCTTGAC in 503 
combination with reverse primer 5µ-ATGCCCTCAC CCACTAACAG. The PCR yielded a 0.5 504 
kb fragment for the wildtype allele and a 0.75 kb product for the mutant allele. The age of 505 
experimental animals is given in the figure legends. All animal work conformed to United 506 
Kingdom legislation (Scientific Procedures) Act 1986 and to the University of Edinburgh 507 
Ethical Review Committee policy; Home Office project license No. P0F4A25E9. 508 
 509 
Myelin purification  510 
A light-weight membrane fraction enriched for myelin was purified from sciatic nerves of mice 511 
by sucrose density centrifugation and osmotic shocks as described (41,52). Myelin 512 
accumulates at the interface between 0.29 and 0.85 M sucrose. Prx-/- and wild type control 513 
C57Bl/6 mice were sacrificed by cervical dislocation at postnatal day 21 (P21). For each 514 
genotype, myelin was purified as three biological replicates (n=3); each biological replicate 515 
representing a pool of 20 sciatic nerves dissected from 10 mice. Protein concentration was 516 
determined using the DC Protein Assay Kit (Bio-Rad).  517 
 518 
Filter-aided sample preparation for proteome analysis 519 
Protein fractions corresponding to 10 ȝg myelin protein were dissolved and processed 520 
according to a filter-aided sample preparation (FASP) protocol essentially as previously 521 
described for synaptic protein fractions (96) and as adapted to CNS myelin (52,97). Unless 522 
stated otherwise, all steps were automated on a liquid-handling workstation equipped with a 523 
vacuum manifold (Freedom EVO 150, Tecan) by using an adaptor device constructed in-524 
house. Briefly, myelin protein samples were lysed and reduced in lysis buffer (7 M urea, 2 M 525 
thiourea, 10 mM DTT, 0.1 M Tris pH 8.5) containing 1% ASB-14 by shaking for 30 min at 526 
37°C. Subsequently, the sample was diluted with ~10 volumes lysis buffer containing 2% 527 
CHAPS to reduce the ASB-14 concentration and loaded on centrifugal filter units (30 kDa 528 
MWCO, Merck Millipore). After removal of the detergents by washing twice with wash buffer 529 
(8 M urea, 10 mM DTT, 0.1 M Tris pH 8.5), proteins were alkylated with 50 mM 530 
iodoacetamide in 8 M urea, 0.1 M Tris pH 8.5 (20 min at RT), followed by two washes with 531 
wash buffer to remove excess reagent. Buffer was exchanged by washing three times with 532 
50 mM ammonium bicarbonate (ABC) containing 10 % acetonitrile. After three additional 533 
washes with 50 mM ABC/10% acetonitrile, which were performed by centrifugation to ensure 534 
quantitative removal of liquids potentially remaining underneath the ultrafiltration membrane, 535 
proteins were digested overnight at 37°C with 400 ng trypsin in 40 µl of the same buffer. 536 
Tryptic peptides were recovered by centrifugation followed by two additional extraction steps 537 
with 40 µl of 50 mM ABC and 40 µl of 1% trifluoroacetic acid (TFA), respectively. Aliquots of 538 
the combined flow-throughs were spiked with 10 fmol/ȝl of \east enolase-1 tryptic digest 539 
standard (Waters Corporation) for quantification purposes and directly subjected to analysis 540 
by liquid chromatography coupled to electrospray mass spectrometry (LC-MS). A pool of all 541 
samples was injected at least before and after any sample set to monitor stability of 542 
instrument performance. 543 
 544 
Mass spectrometry 545 
Nanoscale reversed-phase UPLC separation of tryptic peptides was performed with a 546 
nanoAcquit\ UPLC s\stem equipped with a S\mmetr\ C18 5 ȝm, 180 ȝm î 20 mm trap 547 
column and a HSS T3 C18 1.8 ȝm, 75 ȝm î 250 mm anal\tical column (Waters Corporation) 548 
maintained at 45°C. Injected peptides were trapped for 4 min at a flow rate of 8 µl/min 0.1% 549 
TFA and then separated over 120 min at a flow rate of 300 nl/min with a gradient comprising 550 
two linear steps of 3-35% mobile phase B in 105 min and 35-60% mobile phase B in 15 min, 551 
respectively. Mobile phase A was water containing 0.1% formic acid while mobile phase B 552 
was acetonitrile containing 0.1% formic acid. Mass spectrometric analysis of tryptic peptides 553 
was performed using a Synapt G2-S quadrupole time-of-flight mass spectrometer equipped 554 
with ion mobility option (Waters Corporation). Positive ions in the mass range m/z 50 to 2000 555 
were acquired with a typical resolution of at least 20.000 FWHM (full width at half maximum) 556 
and data were lock mass corrected post-acquisition. UDMSE and DRE-UDMSE analyses 557 
were performed in the ion mobility-enhanced data-independent acquisition mode with drift 558 
time-specific collision energies as described in detail by Distler et al. (48,49). Specifically, for 559 
DRE-UDMSE a deflection device (DRE lens) localized between the quadrupole and the ion 560 
mobility cell of the mass spectrometer was cycled between full (100% for 0.4 sec) and 561 
reduced (5% for 0.4 sec) ion transmission during one 0.8 sec full scan. Continuum LC-MS 562 
data were processed for signal detection, peak picking, and isotope and charge state 563 
deconvolution using Waters ProteinLynx Global Server (PLGS) version 3.0.2 (47). For 564 
protein identification, a custom database was compiled by adding the sequence information 565 
for yeast enolase 1 and porcine trypsin to the UniProtKB/Swiss-Prot mouse proteome and by 566 
appending the reversed sequence of each entry to enable the determination of false 567 
discovery rate (FDR). Precursor and fragment ion mass tolerances were automatically 568 
determined by PLGS 3.0.2 and were typically below 5 ppm for precursor ions and below 10 569 
ppm (root mean square) for fragment ions. Carbamidomethylation of cysteine was specified 570 
as fixed and oxidation of methionine as variable modification. One missed trypsin cleavage 571 
was allowed. Minimal ion matching requirements were two fragments per peptide, five 572 
fragments per protein, and one peptide per protein. The FDR for protein identification was set 573 
to 1% threshold. 574 
 575 
Analysis of proteomic data  576 
For each genotype (Prx-/- and wild type control mice sacrificed at P21), biochemical fractions 577 
enriched for PNS myelin were analyzed as three biological replicates (n=3 per condition); 578 
each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. The 579 
samples were processed with replicate digestion and injection, resulting in four technical 580 
replicates per biological replicate and thus a total of 12 LC-MS runs per condition to be 581 
compared, essentially as previously reported for CNS myelin (36,97). The freely available 582 
software ISOQuant (www.isoquant.net) was used for post-identification analysis including 583 
retention time alignment, exact mass and retention time (EMRT) and ion mobility clustering, 584 
peak intensity normalization, isoform/homology filtering and calculation of absolute in-sample 585 
amounts for each detected protein (48,49,98) according to the TOP3 quantification approach 586 
(53,54). Only peptides with a minimum length of seven amino acids that were identified with 587 
scores above or equal to 5.5 in at least two runs were considered. FDR for both peptides and 588 
proteins was set to 1% threshold and only proteins reported by at least two peptides (one of 589 
which unique) were quantified using the TOP3 method. The parts per million (ppm) 590 
abundance values (i.e. the relative amount (w/w) of each protein in respect to the sum over 591 
all detected proteins) were log2-transformed and normalized by subtraction of the median 592 
derived from all data points for the given protein. Significant changes in protein abundance 593 
were detected by moderated t-statistics essentially as described (96,97) across all technical 594 
replicates using an empirical Bayes approach and false discovery (FDR)-based correction for 595 
multiple comparisons (100). For this purpose, the Bioconductor R packages "limma" (101) 596 
and "q-value" (102) were used in RStudio, an integrated development environment for the 597 
open source programming language R. Proteins identified as contaminants (e.g. components 598 
of blood or hair cells) were removed from the analysis. Proteins with ppm values below 100 599 
which were not identified in one genotype were considered as just above detection level and 600 
also removed from the analysis. The relative abundance of a protein in myelin was accepted 601 
as altered if both statistically significant (q-value <0.05). Pie charts, heatmaps and volcano 602 
plots were prepared in Microsoft Excel 2013 and GraphPad Prism 7. Pearson¶s correlation 603 
coefficients derived from log2-transformed ppm abundance values were clustered and 604 
visualized with the tool heatmap.2 contained in the R package gplots (CRAN.R-605 
project.org/package=gplots). Only pairwise complete observations were considered to 606 
reduce the influence of missing values on clustering behavior. The mass spectrometry 607 
proteomics data have been deposited to the ProteomeXchange Consortium 608 
(proteomecentral.proteomexchange.org) via the PRIDE partner repository (103) with the 609 
dataset identifier PXD015960. 610 
 611 
Gel electrophoresis and silver staining of gels 612 
Protein concentration was determined using the DC Protein Assay kit (BioRad). Samples 613 
were separated on a 12% SDS-PAGE for 1 h at 200 V using the BioRad system, fixated 614 
overnight in 10% [v/v] acetic acid and 40 % [v/v] ethanol and then washed in 30% ethanol (2x 615 
20 min) and ddH2O (1x 20 min). For sensitization, gels were incubated 1 min in 0.012% [v/v] 616 
Na2S2O3 and subsequently washed with ddH2O (3x 20 sec). For silver staining, gels were 617 
impregnated for 20 min in 0.2 % [w/v] AgNO3 / 0.04% formaldehyde, washed with ddH2O (3x 618 
20 sec) and developed in 3% [w/v] Na2CO3 / 0.02% [w/v] formaldehyde. The reaction was 619 
stopped by exchanging the solution with 5% [v/v] acetic acid. 620 
 621 
Immunoblotting 622 
Immunoblotting was performed as described (104,105). Primary antibodies were specific for 623 
dystrophin-related-protein 2 (DRP2; Sigma; 1:1000), peripheral myelin protein 2 (PMP2; 624 
ProteinTech Group 12717-1-AP; 1:1000), proteolipid protein (PLP/DM20; A431 (106); 625 
1:5000), Monocarboxylate transporter 1 (MCT1/SLC16A1; (107); 1:1000), periaxin (PRX; 626 
(59); 1:1000), sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1; 1:2000; 627 
Abcam #13736-1-AP), myelin protein zero (MPZ/P0; (108); kind gift by J. Archelos-Garcia; 628 
1:10.000), voltage-dependent anion-selective channel protein (VDAC; Abcam #ab15895; 629 
1:1000), basigin (BSG/CD147; ProteinTech Group #ab64616; 1:1000), neurofilament H 630 
(NEFH/NF-H; Covance #SMI-32P; 1:1000), voltage-gated potassium channel subunit A 631 
member 1 (KCNA1; Neuromab #73-007; 1:1000), EGR2/KROX20 ((109); kind gift by D. 632 
Meijer, Edinburgh; 1:1000) and myelin basic protein (MBP; 1:2000). To generate the latter 633 
antisera, rabbits were immunized (Pineda Antikörper Service, Berlin, Germany) with the 634 
KLH-coupled peptide CQDENPVVHFFK corresponding to amino acids 212-222 of mouse 635 
MBP isoform 1 (Swisprot/Uniprot-identifier P04370-1). Anti-MBP antisera were purified by 636 
affinity chromatography and extensively tested for specificity by immunoblot analysis of 637 
homogenate of brains dissected from wild-type mice compared to Mbpshiverer/shiverer mice that 638 
lack expression of MBP. Appropriate secondary anti-mouse or -rabbit antibodies conjugated 639 
to HRP were from dianova. Immunoblots were developed using the Enhanced 640 
Chemiluminescence Detection kit (Western Lightning® Plus, Perkin Elmer) and detected with 641 
the Intas ChemoCam system (INTAS Science Imaging Instruments GmbH, Göttingen, 642 
Germany).  643 
 644 
Immunolabelling of teased fibers  645 
Teased fibers were prepared as previously described (9,110). For each genotype, one male 646 
mouse was sacrificed by cervical dislocation at P17. Immunolabelling of teased fibers was 647 
performed as described (69). Briefly, teased fibers were fixed for 5 min in 4% 648 
paraformaldehyde, permeabilized 5 min with ice-cold methanol, washed in PBS (3x 5 min) 649 
and blocked for 1 h at 21°C in blocking buffer (10% horse serum, 0.25% Triton X-100, 1% 650 
bovine serum albumin in PBS). Primary antibodies were applied overnight at 4°C in 651 
incubation buffer (1.5% horse serum, 0.25% Triton X-100 in PBS). Samples were washed in 652 
PBS (3x 5 min) and secondary antibodies were applied in incubation buffer (1 h, RT). 653 
Samples were again washed in PBS (2x 5 min), and 4µ,6-diamidino-2-phenylindole (DAPI; 654 
1:50 000 in PBS) was applied for 10 min at RT. Samples were briefly washed 2x with ddH2O 655 
and mounted using Aqua-Poly/Mount (Polysciences, Eppelheim, Germany). Antibodies were 656 
specific for myelin-associated glycoprotein (MAG clone 513; Chemicon MAB1567; 1:50) and 657 
MCT1/SLC16A1 (107). Secondary antibodies were donkey Į-rabbit-Alexa488 (Invitrogen 658 
A21206; 1:1000) and donkey Į-mouse-Alexa555 (Invitrogen A21202; 1:1000). Labeled 659 
teased fibers were imaged using the confocal microscope Leica SP5. The signal was 660 
collected with the objective HCX PL APO lambda blue 63.0.x1.20. DAPI staining was excited 661 
with 405 nm and collected between 417 nm - 480 nm. To excite the Alexa488 fluorophore an 662 
Argon laser with the excitation of 488 nm was used and the emission was set to 500 nm - 663 
560 nm. Alexa555 was excited by using the DPSS561 laser at an excitation of 561 nm and 664 
the emission was set to 573 nm - 630 nm. To export and process the images LAS AF lite and 665 
Adobe Photoshop were used. 666 
 667 
mRNA abundance profiles 668 
Raw data were previously established (60) from the sciatic nerves of wild type Sprague 669 
Dawley rats at the indicated ages (E21, P6, P18; n=4 per time point). Briefly, sciatic nerves 670 
were dissected, the epineurium was removed, total RNA was extracted with the RNeasy Kit 671 
(Qiagen), concentration and quality (ratio of absorption at 260/280 nm) of RNA samples were 672 
determined using the NanoDrop spectrophotometer (ThermoScientific), integrity of the 673 
extracted RNA was determined with the Agilent 2100 Bioanalyser (Agilent Technologies) and 674 
RNA-Seq was performed using the Illumina HiSeq2000 platform. RNA-Seq raw data are 675 
available under the GEO accession number GSE115930 (60). For the present analysis, the 676 
fastqfiles were mapped to rattus norvegicus rn6 using Tophat Aligner and then quantified 677 
based on the Ensemble Transcripts release v96. The raw read counts were then normalized 678 
using the R package DESeq2. The normalized gene expression data was then standardized 679 
to a mean of zero and a standard deviation of one, therefore genes with similar changes in 680 
expression are close in the euclidian space. Clustering was performed on the standardized 681 
data using the R package mfuzz. Transcripts displaying abundance differences of less than 682 
10% coefficient of variation were considered developmentally unchanged. 683 
 684 
Venn diagrams 685 
Area-proportional Venn diagrams were prepared using BioVenn (111) at www.biovenn.nl/. 686 
 687 
GO-term 688 
For functional categorization of the myelin proteome the associated gene ontology terms 689 
were systematically analyzed on the mRNA abundance cluster using the Database for 690 
Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov). For 691 
comparison known myelin proteins according to literature were added. 692 
 693 
Histological analysis 694 
Prx-/- and control mice were perfused at the indicated ages intravascularly with fixative 695 
solution (2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M sodium cacodylate buffer, pH 696 
7.4). Quadriceps nerves were removed, fixed for 2 h at room temperature, followed by 18 h 697 
at 4°C in the same fixative, postfixed in OsO4, dehydrated a graded series of ethanol, 698 
followed by propylene oxide and embedded in Araldite. All axons not associated with a 699 
Remak bundle were counted and categorized as myelinated or non-myelinated. All myelin 700 
profiles lacking a recognizable axon were counted. The total number of axons were counted 701 
on micrographs of toluidine blue stained Araldite sections (0.5 µm) of quadriceps nerves. 702 
Precise p-values for the quantitative comparison between Ctrl and Prx-/- mice were: Total 703 
number of axons (Figure 6B; Student¶s unpaired t-test): 2 mo p=0.01734; 4 mo p=2.1E-05; 9 704 
mo p=0.007625; Number of myelinated axons (Figure 6C; Student¶s unpaired t-test): 2 mo 705 
p=0.00444; 4 mo p=2.12E-05; 9 mo p=0.005766; Number of empty myelin profiles (Figure 706 
6D; Student¶s unpaired t-test): 2 mo p=0.004445; 4 mo p=0.001461; 9 mo p=0.000695; 707 
Axonal diameters (Figure 6E-G; two-sided Kolmogorow-Smirnow test): 2 mo p=2.20E-16; 4 708 
mo p=2.20E-16; 9 mo p=2.20E-16.  709 
 710 
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Figure 1. Proteome analysis of peripheral myelin 1111 
(A) Schematic illustration of a previous approach to the peripheral myelin proteome (41) 1112 
compared with the present workflow. Note that the current workflow allows largely automated 1113 
sample processing and omits labor-intense 2-dimensional differential gel-electrophoresis, 1114 
thereby considerably reducing hands-on time. Nano LC-MS analysis by data-independent 1115 
acquisition (DIA) using three different data acquisition modes provides efficient identification 1116 
and quantification of abundant myelin proteins (MSE; see Figure 2), a comprehensive 1117 
inventory (UDMSE; see Figures 3-4) and gel-free differential analysis of hundreds of distinct 1118 
proteins (DRE-UDMSE; see Figure 5). Samples were analyzed in three biological replicates.  1119 
(B) Immunoblot of myelin biochemically enriched from sciatic nerves of wild-type mice at 1120 
postnatal day 21 (P21). Equal amounts of corresponding nerve lysate were loaded to 1121 
compare the abundance of marker proteins for compact myelin (MPZ/P0, MBP, PMP2), non-1122 
compact myelin (PRX), the Schwann cell nucleus (KROX20/EGR2), axons (NEFH, KCNA1) 1123 
and mitochondria (VDAC). Blots show n=2 biological replicates representative of n=3 1124 
biological replicates. Note that myelin markers are enriched in purified myelin; other cellular 1125 
markers are reduced.  1126 
(C) Number and relative abundance of proteins identified in myelin purified from the sciatic 1127 
nerves of wild-type mice using three different data acquisition modes (MSE, UDMSE, DRE-1128 
UDMSE). Note that MSE (orange) provides the best information about the relative abundance 1129 
of high-abundant myelin proteins (dynamic range of more than four orders of magnitude) but 1130 
identifies comparatively fewer proteins in purified myelin. UDMSE (blue) identifies the largest 1131 
number of proteins but provides only a lower dynamic range of about three orders of 1132 
magnitude. DRE-UDMSE (green) identifies an intermediate number of proteins with an 1133 
intermediate dynamic range of about four orders of magnitude. Note that MSE with very high 1134 
dynamic range is required for the quantification of the exceptionally abundant myelin protein 1135 
zero (MPZ/P0), myelin basic protein (MBP) and periaxin (PRX). ppm, parts per million. 1136 
(D) Venn diagram comparing the number of proteins identified in PNS myelin by MSE, 1137 
UDMSE and DRE-UDMSE. Note the high overlap of identified proteins.  1138 
(E) Venn diagram of the proteins identified in PNS myelin by UDMSE in this study compared 1139 
with those identified in two previous approaches (41,42).  1140 
 1141 
 1142 
Figure 1-VXSSlemeQW 1. ClXVWeUed heaWmaS Rf PeaUVRQ¶V cRUUelaWiRQ cRefficieQWV for 1143 
protein abundance comparing data acquisition modes. 1144 
The heatmap compares the log2 transformed ppm protein abundance values to assess 1145 
peripheral myelin purified from wild type mice using three data acquisition modes (MSE, 1146 
UDMSE, DRE-UDMSE). The inset shows the color key and the histogram for the values of the 1147 
correlation coefficients. Note that the runs cluster with a high overall correlation (>0.75) into 1148 
three conditions defined by the acquisition mode, in agreement with the experimental design. 1149 
Among the samples analyzed by different acquisition modes, DRE-UDMSE similarly 1150 
correlates with both MSE and UDMSE, reflecting its intermediate nature.  1151 
 1152 
 1153 
Figure 2. Relative abundance of peripheral myelin proteins 1154 
MSE was used to identify and quantify proteins in myelin purified from the sciatic nerves of 1155 
wild-type mice at P21; their relative abundance is given as percent with relative standard 1156 
deviation (% +/- RSD). Note that known myelin proteins constitute >80% of the total myelin 1157 
protein; proteins not previously associated with myelin constitute <20%. Mass spectrometric 1158 
quantification based on 3 biological replicates per genotype with 4 technical replicates each 1159 
(see Figure 1-source data 1).  1160 
 1161 
 1162 
Figure 3. Developmental mRNA abundance profiles of myelin-associated genes 1163 
(A) K-means clustering was performed for the mRNA profiles of those 1046 proteins in our 1164 
myelin proteome inventory for which significant mRNA expression was found by RNA-Seq in 1165 
the sciatic nerve of rats dissected at ages E21, P6, P18 and 6 months (M6). Note that this 1166 
filtering strategy allows to selectively display the developmental abundance profiles of those 1167 
transcripts that encode myelin-associated proteins rather than of all transcripts present in the 1168 
nerve. Standardized mRNA abundance profiles are shown (n=4 biological replicates per 1169 
age). Known myelin genes are displayed in red. For comparison, Pmp22 mRNA was 1170 
included although the small tetraspan protein PMP22 was not mass spectrometrically 1171 
identified due to its unfavorable distribution of tryptic cleavage sites. Normalized counts for all 1172 
mRNAs including those displaying developmentally unchanged abundance are provided in 1173 
Figure 3-Source data 1.  1174 
(B) Numbers of mRNAs per cluster.  1175 
 1176 
 1177 
Figure 4. Categorization of annotated protein functions 1178 
All proteins identified in peripheral myelin by UDMSE (turquoise) and the respective 1179 
developmental expression clusters (Figure 3; shades of red) were analyzed for 1180 
overrepresented functional annotations using gene ontology (GO) terms. The graph displays 1181 
the percentage of proteins in each cluster that were annotated with a particular function. For 1182 
comparison, known myelin proteins were annotated. n.o., not over-represented.  1183 
 1184 
 1185 
Figure 5. Molecular analysis of myelin in the Prx-/- mouse model of CMT4F 1186 
(A) Myelin purified from sciatic nerves dissected from Prx-/- and control mice at P21 was 1187 
separated by SDS-PAGE (0.5 µg protein load) and proteins were visualized by silver 1188 
staining. Bands constituted by the most abundant myelin proteins (MPZ/P0, MBP, PRX) are 1189 
annotated. Note that no band constituted by PRX was detected in Prx-/- myelin and that 1190 
several other bands also display genotype-dependent differences in intensity. Gel shows n=2 1191 
biological replicates representative of n=3 biological replicates.  1192 
(B) The relative abundance of proteins in myelin purified from Prx-/- sciatic nerves as 1193 
quantified by MSE is given as percent with relative standard deviation (% +/- RSD). Note the 1194 
increased relative abundance of MPZ/P0 and MBP compared to wild-type myelin (see 1195 
Figure 2) when PRX is lacking. Mass spectrometric quantification based on 3 biological 1196 
replicates with 4 technical replicates each (see Figure 5-source data 1). 1197 
(C,D) Differential proteome analysis by DRE-UDMSE of myelin purified from Prx-/- and wild-1198 
type mice. Mass spectrometric quantification based on 3 biological replicates per genotype 1199 
with 4 technical replicates each (see Figure 5-source data 2). (C) Top 40 proteins of which 1200 
the abundance is reduced (blue) or increased (red) in peripheral myelin purified from Prx-/- 1201 
compared to wild-type mice with the highest level of significance according to the -log10 1202 
transformed q-value (green). In the heatmaps, each horizontal line corresponds to the fold-1203 
change (FC) of a distinct protein compared to its average abundance in wild-type myelin 1204 
plotted on a log2 color scale. Heatmaps display 12 replicates, i.e. 3 biological replicates per 1205 
genotype with 4 technical replicates each. (D-Dµµµ) Volcano plots representing genotype-1206 
dependent quantitative myelin proteome analysis. Data points represent quantified proteins 1207 
in Prx-/- compared to wild-type myelin and are plotted as the log2-transformed fold-change 1208 
(FC) on the x-axis against the -log10-transformed q-value on the y-axis. Stippled lines mark a 1209 
-log10-transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1210 
Highlighted are the datapoints representing the Top 10 proteins displaying highest zdist 1211 
values (Euclidean distance between the two points (0,0) and (x,y) with x = log2(FC) and y = -1212 
log10(q-value) (red circles in D), immune-related proteins (purple circles in Dµ), proteins of 1213 
the extracellular matrix (ECM; yellow circles in Dµµ) and known myelin proteins (blue circles in 1214 
Dµµµ). n.d., not detected; n.q., no q-value computable due to protein identification in one 1215 
genotype only. Also see Figure 5-supplement 1. 1216 
(E) Immunoblot of myelin purified from Prx-/- and control sciatic nerves confirms the reduced 1217 
abundance of DRP2, SLC16A1/MCT1, BSG and PMP2 in Prx-/- myelin, as found by 1218 
differential DRE-UDMSE analysis (in Figure 5C,D). PRX was detected as genotype control; 1219 
PLP/DM20 and ATP1A1 serve as markers. Blot shows n=2 biological replicates per 1220 
genotype.  1221 
(F) Teased fiber preparations of sciatic nerves dissected from Prx-/- and control mice 1222 
immunolabelled for MAG (red) and SLC16A1 (green). Note that SLC16A1 co-distributes with 1223 
MAG in Schmidt-Lanterman incisures (SLI) in control but not in Prx-/- nerves, in accordance 1224 
with the reduced abundance of SLC16A1 in Prx-/- myelin (Figure 5C-E). Also note that, in 1225 
Prx-/- myelin, SLI were largely undetectable by MAG immunolabeling.  1226 
 1227 
 1228 
Figure 5-VXSSlemeQW 1. ClXVWeUed heaWmaS Rf PeaUVRQ¶V cRUUelaWiRQ cRefficieQWV fRU 1229 
protein abundance comparing genotypes.  1230 
(A) The heatmap compares the log2 transformed ppm protein abundance values from the 1231 
DRE-UDMSE runs to assess peripheral myelin purified from wild type and Prx-/- mice. The 1232 
inset shows the color key and the histogram for the values of the correlation coefficients. 1233 
Note that the runs cluster with a high overall correlation (>0.85) into two conditions defined 1234 
by the genotype, in agreement with the experimental design.  1235 
(B) Volcano plot representing genotype-dependent quantitative myelin proteome analysis. 1236 
Data points represent quantified proteins in Prx-/- compared to wild-type myelin plotted as the 1237 
log2-transformed fold-change (FC) on the x-axis against the -log10-transformed q-value on 1238 
the y-axis. Note the different axis scale compared to Figure 5D. Stippled line marks a -log10-1239 
transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1240 
Highlighted is the datapoint for PRX to illustrate that only trace amounts of PRX were 1241 
detected when assessing Prx-/- myelin. ATP2A1, ATP1A4 and PLCD1 were not detected in 1242 
Prx-/- myelin. 1243 
 1244 
 1245 
Figure 6. Progressive loss and reduced diameters of peripheral axons in Prx-/- mice 1246 
(A-D) Genotype-dependent quantitative assessment of light micrographs of toluidine-stained 1247 
semi-thin sectioned quadriceps nerve dissected at 2, 4 and 9 months of age reveals 1248 
progressive loss of peripheral axons in Prx-/- compared to control mice.  1249 
(A) Representative micrographs. Arrows point at myelinated axons; asterisk denotes an 1250 
unmyelinated axon; arrowhead points at a myelin whorl lacking a recognizable axon. Scale 1251 
bars, 10 µm.  1252 
(B) Total number of axons per nerve that are not associated with a Remak bundle.  1253 
(C) Total number of myelinated axons per nerve. 1254 
(D) Total number per nerve of myelin whorls that lack a recognizable axon.  1255 
Mean +/ SD, n=3-4 mice per genotype and age; *P<0.05, **P<0.01, ***P<0.001 by Student¶s 1256 
unpaired t-test.  1257 
(E-G) Genotype-dependent assessment of myelinated axons shows a shift toward reduced 1258 
axonal diameters in quadriceps nerves of Prx-/- compared to control mice at 2 months (E), 4 1259 
months (F) and 9 months (G) of age. Data are presented as frequency distribution with 0.5 1260 
µm bin width. ***, p<0.001 by two-sided Kolmogorow-Smirnow test. For precise p-values see 1261 
methods section.  1262 
 1263 
 1264 
Figure 1-source data 1. Label-free quantification of proteins in wild-type PNS myelin 1265 
fractions by three different data acquisition modes 1266 
Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1267 
derived from four technical replicates (replicate digestion and replicate injection) per three 1268 
biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1269 
runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; 7 amino 1270 
acids) were identified by database search against the UniprotKB/SwissProt mouse database 1271 
using PLGS. Data were post-processed with the software package ISOQuant to calculate 1272 
absolute in-sample amounts for each detected protein based on the TOP3 approach. 1273 
Reported abundance values are defined as the relative amount of each protein in respect to 1274 
the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1275 
contaminant proteins like keratins were filtered. 1276 
Æ sheet 1: protein identification details 1277 
Æ sheet 2: WT myelin proteome by MSE  1278 
Æ sheet 3: WT myelin proteome by UD-MSE 1279 
Æ sheet 4: WT myelin proteome by DRE UD-MSE 1280 
Æ sheet 5: 45 proteins additionally identified in WT myelin by 1D-gel-LC-MS 1281 
 1282 
 1283 
Figure 3-source data 1. Normalized developmental mRNA abundance data 1284 
Æ sheet 1: normalized values for all individual 4 biological replicates per age 1285 
Æ sheet 2: normalized values for biological replicates averaged to give mean per age 1286 
 1287 
 1288 
Figure 5-source data 1. Label-free quantification of proteins in PNS myelin fractions 1289 
from Prx-/- mice by MSe 1290 
Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1291 
derived from four technical replicates (replicate digestion and replicate injection) per three 1292 
biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1293 
runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; 7 amino 1294 
acids) were identified by database search against the UniprotKB/SwissProt mouse database 1295 
using PLGS. Data were post-processed with the software package ISOQuant to calculate 1296 
absolute in-sample amounts for each detected protein based on the TOP3 approach. 1297 
Reported abundance values are defined as the relative amount of each protein in respect to 1298 
the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1299 
contaminant proteins like keratins were filtered.  1300 
Æ sheet 1: protein identification details 1301 
Æ sheet 2: Prx-/- myelin proteome by MSE 1302 
 1303 
 1304 
Figure 5-source data 2. Label-free quantification of proteins in PNS myelin fractions 1305 
from WT and Prx-/- mice by DRE-UDMSe 1306 
Identification and quantification data of detected myelin-associated proteins by DRE-UDMSe. 1307 
For each genotype, tryptic peptides derived from four technical replicates (replicate digestion 1308 
and replicate injection) per three biological replicate (20 sciatic nerves pooled from 10 1309 
animals) were analyzed by LC-MS (24 runs in total). Proteins (FDR < 1%; 2 peptides/protein) 1310 
and peptides (FDR < 1%; 7 amino acids) were identified b\ database search against the 1311 
UniprotKB/SwissProt mouse database using PLGS. Data were post-processed with the 1312 
software package ISOQuant to calculate absolute in-sample amounts for each detected 1313 
protein based on the TOP3 approach. Reported abundance values are defined as the 1314 
relative amount of each protein in respect to the sum over all detected proteins (ppm: parts 1315 
per million (w/w) of total protein). Typical contaminant proteins like keratins were filtered. The 1316 
-log10-transformed q-value was plotted against the log2-transformed fold change to obtain 1317 
the volcano plot shown in Figure 5D. As no imputation of missing values was performed, 1318 
proteins exclusive for only one of the conditions do not appear in the volcano plot, but are 1319 
appended at the end of the list. Criteria for statistically significant regulation were as follows: 1320 
fold change of at least 1.5 and q-value below 0.05. 1321 
Æ sheet 1: protein identification details 1322 
Æ sheet 2: comparison of WT vs. Prx-/- myelin proteome by DRE-UDMSE 1323 
 1324 
1325 
 1326 
Protein name Gene Reference TMD Cluster 
     
2-hydroxyacylsphingosine 1-beta-galactosyltransferase Ugt8 Bosio et al., 1996 2 P6-up 
Syntrophin D Snta1 Fuhrmann-Stroissnigg et al., 2012 - P18-up 
Annexin A2 Anxa2 Hayashi et al., 2007 - Descending 
Band 4.1 protein B / 4.1B Epb41l3 Ivanovic et al., 2012 - Descending 
Band 4.1 protein G / 4.1G Epb41l2 Ohno et al., 2006 - P6-up 
Breast carcinoma-amplified sequence 1  Bcas1 Ishimoto et al., 2017 - P6-up 
Cadherin 1/ E-Cadherin Cdh1 Fannon et al., 1995 1 P18-up 
Carbonic anhydrase 2 Ca2 Cammer et al., 1987 - Descending 
Catenin D1 Ctnna1 Murata et al., 2006 - U-shaped 
Catenin ß1 Ctnnb1 Fannon et al., 1995 - Descending 
Caveolin 1 Cav1 Mikol et al., 2002 1 P18-up 
CD9, tetraspanin 29 Cd9 Ishibashi et al., 2004 4 P18-p 
CD59A  Cd59a Funabashi et al., 1994 1 P18-up 
CD47, integrin-associated signal transducer Cd47 Gitik et al., 2011 5 P6-up 
CD81, tetraspanin 28 Cd81 Ishibashi et al., 2004 4 P18-up 
CD82, tetraspanin 27 Cd82 Chernousov et al., 2013 4 P18-up 
CD151, tetraspanin 24 Cd151 Patzig et al., 2011 4 P18-up 
Cell adhesion molecule 4/ NECL4 Cadm4 Spiegel et al., 2007 1 P6-up 
Cell division control protein 42 Cdc42 Benninger et al., 2007 - P6-up 
Cell surface glycoprotein MUC18 Mcam Shi et al., 1998 1 Descending 
Ciliary neurotrophic factor Cntf Rende et al., 1992 - Late-up 
CKLF-like MARVEL TMD-containing 5 Cmtm5 Patzig et al., 2011 4 P6-up 
Claudin-19 Cldn19 Miyamoto et al., 2005 4 P6-up 
Cofilin 1 Cfl1 Sparrow et al., 2012 - Descending 
Crystallin D2 Cryab d'Antonio et al., 2006 - P18-up 
Cyclic nucleotide phosphodiesterase Cnp Matthieu et al., 1980 - P6-up 
SaUcogl\can į Sgcd Cai et al., 2007 1 Late-up 
Dihydropyrimidinase related protein 1 Crmp1 d'Antonio et al., 2006 - Descending 
Disks large homolog 1 Dlg1 Cotter et al., 2010 - Descending 
Dynein light chain 1 Dynll1 Myllykoski et al. 2018 - P6-up 
Dystroglycan Dag1 Yamada et al, 1994 1 P6-up 
Dystrophin/DP116 Dmd Cai et al., 2007 - P6-up 
Dystrophin-related protein 2 Drp2 Sherman et al., 2001 - P18-up 
E3 ubiquitin-protein ligase NEDD4 Nedd4 Liu et al., 2009 - Descending 
Ezrin Ezr Scherer et al., 2001 - P6-up 
Fatty acid synthase Fasn Salles et al., 2002 - P6-up 
Flotillin 1 Flot1 Lee et al., 2014 - P18-up 
Gap junction ß1 protein / Cx32 Gjb1 Li et al., 2002 4 P18-up 
Gap junction Ȗ3 protein / Cx29 Gjc3 Li et al., 2002 1 P6-up 
Gelsolin Gsn Gonçalves et al., 2010 - Late-up 
Glycogen synthase kinase 3ß Gsk3b Ogata et al., 2004 - P6-up 
Integrin D6 Itga6 Nodari et al., 2008 1 P6-up 
Integrin DV Itgav Chernousov & Carey, 2003 1 Descending 
Integrin ß1  Itgb1 Feltri et al., 2002 1 Descending 
Integrin ß4 Itgb4 Quattrini et al., 1996 2 P18-up 
Junctional adhesion molecule C Jam3 Scheiermann et al., 2007 1 P18-up 
Laminin D2 Lama2 Yang et al., 2005 - P6-up 
Laminin D4 Lama4 Yang et al., 2005 - Descending 
Laminin ß1 Lamb1 LeBeau et al., 1994 - Descending 
Laminin ß2 Lamb2 LeBeau et al., 1994 - P18-up 
Laminin Ȗ1 Lamc1 Chen & Strickland, 2003 - Descending 
Membrane Palmitoylated Protein 6 Mpp6 Saitoh et al., 2019 - P6-up 
Microtubule-associated protein 1A Map1a Fuhrmann-Stroissnigg et al., 2012 - P18-up 
Microtubule-associated protein 1B Map1b Fuhrmann-Stroissnigg et al., 2012 - P6-up 
Mitogen-activated protein kinase 1/ ERK2 Mapk1 Mantuano et al., 2015 - Descending 
Mitogen-activated protein kinase 3/ ERK1 Mapk3 Mantuano et al., 2015 - P18-up 
Moesin Msn Scherer et al., 2001 - Unchanged 
Monocarboxylate transporter 1 Slc16a1 Domenech-Estevez et al., 2015 11 P18-up 
Myelin associated glycoprotein Mag Figlewicz et al., 1981 1 P6-up 
Myelin basic protein Mbp Boggs, 2006 - P6-up 
Myelin protein 2 Pmp2 Trapp et al., 1984 - P18-up 
Myelin protein zero/ P0 Mpz Giese et al., 1992 1 P6-up 
Myelin proteolipid protein Plp1 Garbern et al., 1997 4 P6-up 
Myotubularin-related protein 2 Mtmr2 Bolino et al., 2004 - P6-up 
Noncompact myelin-associated protein Ncmap Ryu et al., 2008 1 P18-up 
NDRG1, N-myc downstream regulated Ndrg1 Berger et al., 2004 - P18-uP 
Neurofascin Nfasc Tait et al., 2000 2 P18-up 
Nidogen 1 Nid1 Lee et al., 2007 - Descending 
P2X purinoceptor 7 P2rx7 Faroni et al., 2014 - P6-up 
Paxillin Pxn Fernandez-Valle et al., 2002 - P6-up 
Periaxin Prx Gillespie et al., 1994 - P6-up 
Plasmolipin Pllp Bosse et al., 2003 4 P18-up 
Profilin 1 Pfn1 Montani et al., 2014 - Descending 
Lin-7 homolog C Lin7c Saitoh et al., 2017 - P6-up 
Rac1 Rac1 Benninger et al., 2007 - U-Shaped 
Radixin Rdx Scherer et al., 2001 - Descending 
RhoA Rhoa Brancolini et al., 1999 - U-Shaped 
Septin 2 Sept 2 Buser et al., 2009 - Descending 
Septin 7 Sept 7 Buser et al., 2009 - U-Shaped 
Septin 8 Sept 8 Patzig et al., 2011 - P18-up 
Septin 9 Sept 9 Patzig et al., 2011 - P6-up 
Septin 11 Sept 11 Buser et al., 2009 - Descending 
Sirtuin 2, NAD-dependent deacetylase Sirt2 Werner et al., 2007 - P18-up 
Spectrin alpha chain, non-erythrocytic 1 Sptan1 Susuki et al., 2018 - P18-up 
Spectrin beta chain, non-erythrocytic 1 Sptbn1 Susuki et al., 2018 - P18-up 
Tight junction protein ZO-1 Tjp1 Poliak et al., 2007 - P6-up 
Tight junction protein ZO-2 Tjp2 Poliak et al., 2007 - P6-up 
Transferrin Tf Liu et al., 1990 2 Late-up 
Vimentin Vim Triolo et al., 2012 - Unchanged  
Vinculin Vcl Beppu et al., 2015 - Descending 
Table 1. Known myelin proteins in the myelin proteome. Proteins mass-spectrometrically identified in peripheral myelin 1327 
are compiled according to availability of prior references as myelin proteins. Given are the official gene name, one selected 1328 
reference, the number of transmembrane domains (TMD) and the mRNA abundance profile cluster (see Figure 3).  1329 
 1330 
1331 
 1332 
Protein name Gene name OMIM# Gene Locus Neuropathy 
Monoacylglycerol lipase ABHD12 ABHD12 613599 20p11.21 PHARC 
Apoptosis-inducing factor 1  AIFM1 300169 Xq26.1 CMTX4, DFNX5 
Na+/K+ -transporting ATPase D ATP1A1 182310 1p13.1 CMT2DD 
Cytochrome c oxidase subunit 6A1  COX6A1 602072 12q24.31 CMTRID 
Dystrophin-related protein 2 DRP2 300052 Xq22.1   CMTX 
Dynactin subunit 1 DCTN1 601143 2p13.1 DHMN7B 
Dynamin 2 DNM2 602378 19p13.2 CMT2M, CMTDIB 
Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 600112 14q32.31 CMT20, SMALED1 
E3 SUMO-protein ligase EGR2 129010 10q21.3 CMT1D, CMT3, CMT4E 
Glycine-tRNA ligase GARS (Gart) 600287 7p14.3 CMT2D, HMN5A 
Gap junction ß1 protein / Cx32 GJB1 304040 Xq13.1 CMTX1 
Guanine nucleotide-binding protein ß4 GNB4 610863 3q26.33 CMTDIF 
Histidine triad nucleotide-binding protein 1 HINT1 601314 5q23.3 NMAN 
Hexokinase 1 HK1 142600 10q22.1 CMT4G 
Heat shock protein ß1 HSPB1 602195 7q11.23 CMT2F, DHMN2B 
Kinesin heavy chain isoform 5A KIF5A 602821 12q13.3 SPG10 
Prelamin A/C LMNA 150330 1q22 CMT2B1 
Neprilysin MME 120520 3q25.2 CMT2T, SCA43 
Myelin protein zero/ P0 
 
 
MPZ 
 
 
159440 
 
 
1q23.3 
 
 
CHN2,CMT1B, CMT2I, 
CMT2J,CMT3, CMTDID, 
Roussy-Levy syndrome 
Myotubularin-related protein 2 MTMR2 603557 11q21 CMT4B1 
Alpha-N-acetylglucosaminidase NAGLU (NAGA) 609701 17q21.2 CMT2V 
NDRG1, N-myc downstream regulated NDRG1 605262 8q24.22 CMT4D 
Neurofilament heavy polypeptide NEFH 162230 22q12.2 CMT2CC 
Neurofilament light polypeptide NEFL 162280 8p21.2 CMT2E, CMT1F, CMTDIG 
Peripheral myelin protein 2 PMP2 170715 8q21.13 CMT1G 
Peripheral myelin protein 22 
 
 
PMP22 
 
 
601907 
 
 
17p12 
 
 
CMT1A, CMT1E, CMT3, 
HNPP,  
Roussy-Levy syndrome 
Ribose-phosphate pyrophosphokinase 1 
 
PRPS1 
 
311850 
 
Xq22.3 
 
Arts syndrome, CMTX5, 
DFNX1 
Periaxin PRX 605725 19q13.2 CMT4F, CMT3 
Ras-related protein Rab 7a RAB7A 602298 3q21.3 CMT2B 
Septin 9 SEPT9 604061 17q25.3 HNA 
Transitional ER-ATPase VCP 601023 9p13.3 CMT2Y 
Tryptophan-tRNA ligase, cytoplasmic WARS 191050 14q32.32 HMN9 
Tyrosine-tRNA ligase, cytoplasmic YARS 603623 1p35.1 DI-CMTC 
Table 2. Peripheral myelin proteins identified in PNS myelin involved in neuropathological diseases. Proteins 1333 
massspectrometically identified in peripheral myelin were analyzed regarding the involvement of the ortholog human gene 1334 
in neuropathological diseases. PMP22 was added, though it was not identified by MS analyses due to its unfavorable 1335 
distribution of tryptic cleavage sites. CMT, Charcot-Marie-Tooth disease; DHMN, distal hereditary motor neuropathy; DI-1336 
CMTC, dominant intermediate CMTC; DFN, X-linked deafness; HMN, hereditary motor neuropathy; HSAN, hereditary 1337 
sensory and autonomic neuropathy; HNA, hereditary sensory and autonomic neuropathy; OMIM, Online Mendelian 1338 
Inheritance in Man; PHARC, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract; SCA, spinocerebellar 1339 
ataxia; SPG, spastic paraplegia. 1340 
 1341 
Siems et al., Figure 1
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48 
ABSTRACT 49 
 50 
Proteome and transcriptome analyses aim at comprehending the molecular profiles of the 51 
brain, its cell-types and subcellular compartments including myelin. Despite the relevance of 52 
the peripheral nervous system for normal sensory and motor capabilities, analogous 53 
approaches to peripheral nerves and peripheral myelin have fallen behind evolving technical 54 
standards. Here we assess the peripheral myelin proteome by gel-free, label-free mass-55 
spectrometry for deep quantitative coverage. Integration with RNA-Sequencing-based 56 
developmental mRNA-abundance profiles and neuropathy disease genes illustrates the utility 57 
of this resource. Notably, the periaxin-deficient mouse model of the neuropathy Charcot-58 
Marie-Tooth 4F displays a highly pathological myelin proteome profile, exemplified by the 59 
discovery of reduced levels of the monocarboxylate transporter MCT1/SLC16A1 as a novel 60 
facet of the neuropathology. This work provides the most comprehensive proteome resource 61 
thus far to approach development, function and pathology of peripheral myelin, and a 62 
straightforward, accurate and sensitive workflow to address myelin diversity in health and 63 
disease.  64 
 65 
66 
INTRODUCTION 67 
 68 
The ensheathment of axons with myelin enables rapid impulse propagation, a prerequisite 69 
for normal motor and sensory capabilities of vertebrates (1,2). This is illustrated by 70 
demyelinating neuropathies of the Charcot-Marie-Tooth (CMT) spectrum, in which mutations 71 
affecting myelin genes as MPZ, PMP22, GJB1 and PRX impair myelin integrity and reduce 72 
the velocity of nerve conduction in the peripheral nervous system (PNS) (3). 73 
Developmentally, myelination by Schwann cells in peripheral nerves is regulated by axonal 74 
neuregulin-1 (4,5) and the basal lamina (6±8) that is molecularly linked to the abaxonal 75 
Schwann cell membrane via integrins and the dystroglycan complex (9±12). In adulthood, 76 
the basal lamina continues to enclose all axon/myelin-units (13), probably to maintain myelin. 77 
Beyond regulation by extracellular cues, myelination involves multiple proteins mediating 78 
radial sorting of axons out of Remak bundles, myelin membrane growth and layer 79 
compaction (14±18). For example, the Ig-domain containing myelin protein zero (MPZ; also 80 
termed P0) mediates adhesion between adjacent extracellular membrane surfaces in 81 
compact myelin (19). At their intracellular surfaces, myelin membranes are compacted by the 82 
cytosolic domain of MPZ/P0 together with myelin basic protein (MBP; previously termed P1) 83 
(20,21). Not surprisingly, MPZ/P0 and MBP were early identified as the most abundant 84 
peripheral myelin proteins (22,23).  85 
 86 
A system of cytoplasmic channels through the otherwise compacted myelin sheath remains 87 
non-compacted throughout life, i.e. the adaxonal myelin layer, paranodal loops, Schmidt-88 
Lanterman incisures (SLI), and abaxonal longitudinal and transverse bands of cytoplasm 89 
termed bands of Cajal (14,24,25). Non-compacted myelin comprises cytoplasm, cytoskeletal 90 
elements, vesicles and lipid-modifying enzymes, and thus numerous proteins involved in 91 
maintaining the myelin sheath. The cytosolic channels probably also represent transport 92 
routes toward Schwann cell-dependent metabolic support of myelinated axons (26±31).  93 
 94 
Considering that Schwann cells constitute a major proportion of the cells in the PNS, 95 
oligonucleotide microarray analyses have been used for mRNA abundance profiling of total 96 
sciatic nerves (32,33). Indeed, these systematic approaches allowed the identification of 97 
novel myelin constituents including non-compact myelin-associated protein (NCMAP/MP11) 98 
(34). Notwithstanding that the number of known peripheral myelin proteins has grown in 99 
recent years, a comprehensive molecular inventory has been difficult to achieve because 100 
applications of s\stematic (µomics¶) approaches specificall\ to Schwann cells and peripheral 101 
myelin remained comparatively scarce, different from studies addressing oligodendrocytes 102 
and CNS myelin (35±40). One main reason may be that the available techniques were not 103 
sufficiently straightforward for general application. For example, the protein composition of 104 
peripheral myelin was previously assessed by proteome analysis (41). However, at that time 105 
the workflow of sample preparation and data acquisition (schematically depicted in Figure 106 
1A) was very labor-intense and required a substantial amount of input material; yet the depth 107 
of the resulting datasets remained limited. In particular, differential myelin proteome analysis 108 
by 2-dimensional fluorescence intensity gel electrophoresis (2D-DIGE) requires considerable 109 
hands-on-time and technical expertise (41,42). While this method is powerful for the 110 
separation of proteoforms (43), it typically suffers from under-representation of highly basic 111 
and transmembrane proteins. It thus allows comparing the abundance of only few myelin 112 
proteins rather than quantitatively covering the entire myelin proteome. Because of these 113 
limitations and an only modest sample-to-sample reproducibility, 2D-DIGE analysis of myelin, 114 
although unbiased, has not been commonly applied beyond specialized laboratories.  115 
 116 
The aim of the present study was to establish a straightforward and readily applicable 117 
workflow to facilitate both comprehensive knowledge about the protein composition of 118 
peripheral myelin and systematic assessment of differences between two states, e.g., 119 
pathological alterations in a neuropathy model. The major prerequisites were the biochemical 120 
purification of myelin, its solubilization with the detergent ASB-14 and the subsequent 121 
automated digestion with trypsin during filter-aided sample preparation (FASP). The tryptic 122 
peptides were fractionated by liquid chromatography and analyzed by mass spectrometry for 123 
gel-free, label-free quantitative proteome analysis. More specifically, we used nano-flow 124 
ultra-performance liquid chromatography (nanoUPLC) coupled to an electrospray-ionization 125 
quadrupole time-of-flight (ESI-QTOF) mass spectrometer with ion mobility option, providing 126 
an orthogonal dimension of peptide separation. The utilized data-independent acquisition 127 
(DIA) strategy relies on collecting data in an alternating low and elevated energy mode 128 
(MSE); it enables simultaneous sequencing and quantification of all peptides entering the 129 
mass spectrometer without prior precursor selection (reviewed in (44,45)). With their high-130 
duty cycle utilized for the acquisition of precursor ions, MSE-type methods are ideally suited 131 
to reliably quantify proteins based on peptide intensities. Notably, these methods do not 132 
involve the use of spectral libraries in the identification of proteins, different from other DIA 133 
strategies. Instead, the achieved high-complexity fragmentation spectra are deconvoluted 134 
before submission to dedicated search engines for peptide and protein identification (46,47). 135 
In the MSE mode, this deconvolution involves precursor-fragment ion alignment solely on the 136 
basis of chromatographic elution profiles; on top, drift times of ion mobility-separated 137 
precursors are used in the high-definition (HD)MSE mode. An expansion of the latter referred 138 
to as the ultra-definition (UD)MSE mode, additionally implements drift time-dependent 139 
collision energy profiles for more effective precursor fragmentation (48,49).  140 
 141 
Indeed, compared to the previously used manual handling and in-gel digestion, the current 142 
workflow (schematically depicted in Figure 1A) is considerably less labor-intense, and 143 
automated FASP increases sample-to-sample reproducibility. Moreover, differential analysis 144 
by quantitative mass spectrometry (MS) facilitates reproducible quantification of hundreds 145 
rather than a few distinct myelin proteins. Together, the present workflow increases the 146 
efficacy of assessing the peripheral myelin proteome while shifting the main workload from 147 
manual sample preparation and gel-separation to automated acquisition and processing of 148 
data. We propose that comprehending the expression profiles of all myelin proteins in the 149 
healthy PNS and in myelin-related disorders can contribute to advancing our understanding 150 
of the physiology and pathophysiology of peripheral nerves.  151 
152 
RESULTS 153 
 154 
Purification of peripheral myelin  155 
We biochemically enriched myelin as a light-weight membrane fraction from pools of sciatic 156 
nerves dissected from mice at postnatal day 21 (P21) using an established protocol of 157 
discontinuous sucrose density gradient centrifugation (41,50), in which myelin membranes 158 
accumulate at the interface between 0.29 and 0.85 M sucrose. By immunoblotting, proteins 159 
specific for both compact (MPZ/P0, MBP, PMP2) and non-compact (PRX) myelin were 160 
substantially enriched in the myelin fraction compared to nerve lysates (Figure 1B). 161 
Conversely, axonal (NEFH, KCNA1) and mitochondrial (VDAC) proteins and a marker for the 162 
Schwann cell nucleus (KROX20/EGR2) were strongly reduced in purified myelin. Together, 163 
these results imply that biochemically purified peripheral myelin is suitable for systematic 164 
analysis of its protein composition. 165 
 166 
Proteome analysis of peripheral myelin 167 
It has long been difficult to accurately quantify the most abundant myelin proteins both in the 168 
CNS (PLP, MBP, CNP (51)) and the PNS (MPZ/P0, MBP, PRX; this work), probably owing to 169 
their exceptionally high relative abundance. For example, the major CNS myelin constituents 170 
PLP, MBP and CNP comprise 17, 8 and 4% of the total myelin protein, respectively (51). We 171 
have recently provided proof of principle (52) that the mass spectrometric quantification of 172 
these high-abundant myelin proteins is accurate and precise when data are acquired in the 173 
MSE data acquisition mode and proteins are quantified according to the TOP3 method, i.e. if 174 
their abundance values are obtained based on the proven correlation between the average 175 
intensity of the three peptides exhibiting the most intense mass spectrometry response and 176 
the absolute amount of their source protein (53,54). Using data acquisition by MSE we 177 
confirmed that CNP constitutes about 4% of the total CNS myelin proteome and that the 178 
abundance of CNP in myelin from mice heterozygous for the Cnp gene (CnpWT/null) compared 179 
to wild-type mice is 50.7% (r0.4%), in agreement with the halved gene dosage and gel-180 
based quantification by silver staining or immunoblotting (52).  181 
 182 
When applying the MSE mode to PNS myelin, we quantified 351 proteins with a false 183 
discovery rate (FDR) of <1% at peptide and protein level and an average sequence coverage 184 
of 35.5% (Figure 1-source data 1). While MSE (labeled in orange in Figure 1C) indeed 185 
provided a dynamic range of more than four orders of magnitude and thus quantitatively 186 
covered the exceptionally abundant myelin proteins MPZ/P0, MBP and PRX, the number of 187 
quantified proteins appeared limited when spectral complexity was deconvoluted solely on 188 
the basis of chromatographic elution profiles. Accordingly, by using the UDMSE mode, which 189 
comprises ion mobility for additional peptide separation as well as drift time-specific collision 190 
energies for peptide fragmentation, proteome coverage was increased about three-fold (1078 191 
proteins quantified; average sequence coverage 34.3%; Figure 1-source data 1). However, 192 
the dynamic range of UDMSE (labeled in blue in Figure 1C) was found to be somewhat 193 
compressed compared to that of MSE, which can be considered an expectable feature of 194 
traveling wave ion mobility devices (55), where the analysis of pulsed ion packages leads to 195 
a temporal and spatial binning of peptides during ion mobility separation. Indeed, this 196 
manifests as a ceiling effect for the detection of exceptionally intense peptide signals, which 197 
results in an underestimation of the relative abundance of MPZ/P0, MBP and PRX by 198 
UDMSE. 199 
 200 
The complementary nature of the MSE and UDMSE data acquisition modes led us to 201 
conclude that a comprehensive analysis of the myelin proteome that facilitates both correct 202 
quantification of the most abundant proteins and deep quantitative coverage of the proteome 203 
would require analyzing the same set of samples with two different instrument settings for 204 
MSE and UDMSE, respectively. Considering that instrument time is a bottleneck for the 205 
routine differential proteome analysis of myelin from mutant mice, we aimed to combine the 206 
strengths of MSE and UDMSE into a single data acquisition mode. Based on a gene ontology 207 
enrichment analysis for cellular components of the 200 proteins of highest and lowest 208 
abundance from the UDMSE dataset, we reali]ed that the µbottomµ of the quantified proteome 209 
is probably largely unrelated to myelin but dominated by contaminants from other subcellular 210 
sources including mitochondria. We thus reasoned that for a myelin-directed data acquisition 211 
mode, proteome depth may be traded in for a gain in dynamic range and devised a novel 212 
method referred to as dynamic range enhancement (DRE)-UDMSE, in which a deflection lens 213 
is used to cycle between full and reduced ion transmission during mass spectrometric 214 
scanning. Indeed, DRE-UDMSE quantified an intermediate number of proteins in PNS myelin 215 
(554 proteins; average sequence coverage 30.6%; Figure 1-source data 1) while providing 216 
an intermediate dynamic range (labeled in green in Figure 1C). We thus consider DRE-217 
UDMSE as the data acquisition mode of choice most suitable for routine differential myelin 218 
proteome profiling (see below). 219 
 220 
Overall, we found a high reproducibility between replicates and even among the different 221 
data acquisition modes as indicated by Pearson¶s correlation coefficients for protein 222 
abundance in the range of 0.765-0.997 (Figure 1-supplement 1). When comparing the 223 
proteins identified in PNS myelin using the three data acquisition modes, we found a very 224 
high overlap (Figure 1D). We also found a high overlap (Figure 1E) between the proteins 225 
identified in the present study by UDMSE and those detected in previous proteomic 226 
approaches to PNS myelin (41,42), thus allowing a high level of confidence. Together, the 227 
three data acquisition modes exhibit distinct strengths in the efficient quantification of 228 
exceptionally abundant proteins (MSE), establishing a comprehensive inventory (UDMSE) 229 
and gel-free, label-free differential analysis of hundreds of distinct proteins (DRE-UDMSE) in 230 
peripheral myelin (see Figure 1A). Yet, analyzing the same set of samples by different 231 
modes may not always be feasible in all routine applications when considering required 232 
instrument time.  233 
 234 
Relative abundance of peripheral myelin proteins 235 
Considering that MSE provides the high dynamic range required for the quantification of the 236 
most abundant myelin proteins, we calculated the relative abundance of the 351 proteins 237 
identified in myelin by MSE (Figure 1-source data 1). According to quantitative assessment 238 
of this dataset, the most abundant PNS myelin protein, myelin protein zero (MPZ/P0), 239 
constitutes 44% (+/-4% relative standard deviation (RSD)) of the total myelin protein (Figure 240 
2). Myelin basic protein (MBP), periaxin (PRX) and tetraspanin-29 (CD9) constitute 18% (+/-241 
1% RSD), 15% (+/-1%) and 1% (+/-0.2%) of the total myelin protein, respectively (Figure 2). 242 
For MPZ/P0 and MBP, our quantification by MSE is in agreement with but specifies prior 243 
estimations upon gel-separation and protein labeling by Sudan-Black, Fast-Green or 244 
Coomassie-Blue, in which they were judged to constitute 45±70% and 2±26% of the total 245 
myelin protein, respectively (22,56±58). However, gel-based estimates of the relative 246 
abundance of myelin proteins were not very precise with respect to many other proteins, 247 
including those of high molecular weight. Indeed, periaxin was identified as a constituent of 248 
peripheral myelin after the advent of gradient SDS-PAGE gels (59), which allowed improved 249 
migration of large proteins into gels. The present MSE-based quantification of myelin proteins 250 
also extends beyond and partially adjusts an earlier mass spectrometric approach (41). 251 
Indeed, the current approach identified and quantified more myelin proteins, probably owing 252 
to improved protein solubilization during sample preparation and higher dynamic range of the 253 
used mass spectrometer. By MSE, known myelin proteins (Table 1) collectively constitute 254 
over 85% of the total myelin protein (Figure 2) while proteins not yet associated with myelin 255 
account for the remaining 15% of the total myelin protein. 256 
 257 
Comprehensive compendium and comparison to the transcriptome 258 
To systematically elucidate the developmental abundance profiles of the transcripts that 259 
encode peripheral myelin proteins (Figure 3), we used our combined proteome inventory of 260 
peripheral myelin (Figure 1-source data 1) to filter mRNA abundance data of all genes 261 
expressed in sciatic nerves. By this strategy, Figure 3 displays only those transcripts of 262 
which the protein product was identified in peripheral myelin rather than all transcripts in the 263 
nerve, thereby discriminating myelin-related mRNAs from other mRNAs such as those 264 
present in peripheral axons, fibroblasts, immune cells etc. In this assessment we additionally 265 
included PMP22 although it was not detected by MS as well as 45 proteins exclusively 266 
identified by LC-MS of myelin separated by SDS-PAGE (Figure 1-source data 1). For 267 
mRNA abundance profiles, we exploited a recently established RNA sequencing analysis 268 
(RNA-Seq; platform Illumina HiSeq 2000) of sciatic nerves dissected form wild type Sprague 269 
Dawley rats at embryonic day 21 (E21), P6, P18 and 6 months (60). RNA-Seq provides 270 
reliable information about the relative abundance of all significantly expressed genes and is 271 
thus not limited to those represented on the previously used oligonucleotide microarrays 272 
(41). The raw data (accessible under GEO accession number GSE115930) were normalized 273 
(Figure 3-source data 1) and standardized. When comparing the proteome and 274 
transcriptome datasets, significant mRNA abundance was detected for all 1046 transcripts 275 
for which an unambiguous unique gene identifier was found (Figure 3). 126 transcripts 276 
displayed developmentally unchanged abundance levels, i.e., abundance changes below a 277 
threshold of 10% coefficient of variation (Figure 3B; Figure 3-source data 1).  278 
 279 
By fuzzy c-means clustering, those 920 transcripts that showed developmental abundance 280 
changes were grouped into 5 clusters (Figure 3A; Figure 3-source data 1). Among those, 281 
one cluster corresponds to an mRNA-abundance peak coinciding with an early phase of 282 
myelin biogenesis (cluster µP6-UPµ), which includes the highest proportion of known myelin 283 
proteins (Table 1) such as MPZ/P0, MBP, PRX, cyclic nucleotide phosphodiesterase (CNP), 284 
fatty acid synthase (FASN), myelin-associated glycoprotein (MAG), proteolipid protein 285 
(PLP/DM20), cell adhesion molecule-4 (CADM4/NECL4), connexin-29 (GJC3), claudin-19 286 
(CLDN19) and CKLF-like MARVEL-transmembrane domain containing protein-5 (CMTM5). 287 
However, many known myelin proteins clustered together according to their mRNA-288 
abundance peak coinciding with a later phase of myelination (cluster µP18-UPµ), including 289 
peripheral myelin protein 2 (PMP2), tetraspanin-29 (CD9), tetraspanin-28 (CD81), connexin-290 
32 (GJB1), plasmolipin (PLLP), junctional adhesion molecule-3 (JAM3), CD59 and 291 
dystrophin-related protein-2 (DRP2). The proportion of known myelin proteins was lower in 292 
the clusters corresponding to mRNA-abundance peaks in adulthood (clusters µlate-UPµ, µU-293 
shapedµ). Yet, a considerable number of transcripts displayed abundance peaks at the 294 
embryonic time-point (cluster µDescendingµ), including carbonic anhydrase 2 (CA2), cofilin-1 295 
CFL1), tubulin beta-4 (TUBB4b) and band 4.1-protein B (EPB41L3). Generalized, the 296 
clusters were roughly similar when comparing previous oligonucleotide microarray analysis 297 
of mouse sciatic nerves (41) and the RNA-Seq analysis of rat sciatic nerves (this study); yet, 298 
the latter provides information on a larger number of genes and with a higher level of 299 
confidence. Together, clustering of mRNA abundance profiles allows categorizing peripheral 300 
myelin proteins into developmentally co-regulated groups.  301 
 302 
When systematically assessing the proteins identified in myelin by gene ontology (GO)-term 303 
analysis, the functional categories over-represented in the entire myelin proteome included 304 
cell adhesion, cytoskeleton and extracellular matrix (labeled in turquoise in Figure 4). When 305 
analyzing the clusters of developmentally co-expressed transcripts (from Figure 3), proteins 306 
associated with the lipid metabolism were particularly enriched in the P6-UP and P18-UP 307 
clusters, while those associated with the extracellular matrix (ECM) were over-represented in 308 
the U-shaped and Descending clusters (Figure 4). For comparison, known myelin proteins 309 
(Table 1) were over-represented in the P6-UP and P18-UP clusters (Figure 4). Together, 310 
our proteome dataset provides comprehensive in-depth coverage of the protein constituents 311 
of peripheral myelin purified from the sciatic nerves of wild type mice, and comparison to the 312 
transcriptome allows identifying developmentally co-regulated and functional groups of 313 
myelin proteins. Our data thus supply a solid resource for the molecular characterization of 314 
myelin and for discovering functionally relevant myelin proteins.  315 
 316 
Neuropathy genes encoding myelin proteins  317 
Heritable neuropathies can be caused by mutations affecting genes preferentially expressed 318 
in neurons, Schwann cells or both (3,61±63). To systematically assess which neuropathy-319 
causing genes encode peripheral myelin proteins, we compared our myelin proteome 320 
dataset with a current overview about disease genes at the NIH National Library of Medicine 321 
at https://ghr.nlm.nih.gov/condition/charcot-marie-tooth-disease#genes. Indeed, 31 myelin 322 
proteins were identified to be encoded by a proven neuropathy gene (Table 2), a 323 
considerable increase compared to eight disease genes found in a similar previous approach 324 
(41). Notably, this increase is owing to both the larger size of the current myelin proteome 325 
dataset (Figure 1E) and the recent discovery of numerous neuropathy genes by the 326 
widespread application of next generation sequencing.  327 
 328 
Pathological proteomic profile of peripheral myelin in a neuropathy model 329 
The results presented thus far were based on analyzing myelin of healthy wild type mice; yet 330 
we also sought to establish a straightforward method to systematically assess myelin 331 
diversity, as exemplified by alterations in a pathological situation. As a model we chose mice 332 
carrying a homozygous deletion of the periaxin gene (Prx-/-) (26,64). Periaxin (PRX) is the 333 
third-most abundant peripheral myelin protein (Figure 2) and scaffolds the dystroglycan 334 
complex in Schwann cells. Prx-/- mice represent an established model of Charcot-Marie-335 
Tooth disease type 4F (65±67). Aiming to assess the myelin proteome, we purified myelin 336 
from pools of sciatic nerves dissected from Prx-/- and control mice at P21. Upon SDS-PAGE 337 
separation and silver staining the band patterns appeared roughly similar (Figure 5A), with 338 
the most obvious exception of the absence of the high-molecular weight band constituted by 339 
periaxin in Prx-/- myelin. Yet, several other bands also displayed genotype-dependent 340 
differences in intensity. As expected, PRX was also undetectable by MSE in Prx-/- myelin, in 341 
which most of the total myelin protein was constituted by MPZ/P0 and MBP (Figure 5B; 342 
Figure 5-source data 1).  343 
 344 
Upon differential analysis by DRE-UDMSE (Figure 5-source data 2), multiple proteins 345 
displayed genotype-dependent differences as visualized in a heatmap displaying those 40 346 
proteins of which the abundance was reduced or increased with the highest statistical 347 
significance in Prx-/- compared to control myelin (Figure 5C). For example, the abundance of 348 
the periaxin-associated dystrophin-related protein 2 (DRP2) was strongly reduced in Prx-/- 349 
myelin, as previously shown by immunoblotting (9). Notably, the abundance of multiple other 350 
proteins was also significantly reduced in Prx-/- myelin, including the extracellular matrix 351 
protein laminin C1 (LAMC1; previously termed LAMB2), the laminin-associated protein 352 
nidogen (NID1), Ig-like cell adhesion molecules (CADM4, MAG), the desmosomal junction 353 
protein desmin (DES), cytoskeletal and cytoskeleton-associated proteins (EPB41L3, MAP1A, 354 
CORO1A, SPTBN1, various microtubular and intermediate filament monomers), the 355 
monocarboxylate transporter MCT1 (also termed SLC16A1) and the MCT1-associated (68) 356 
immunoglobulin superfamily protein basigin (BSG, also termed CD147). On the other hand, 357 
proteins displaying the strongest abundance increase in Prx-/- myelin included immune-358 
related proteins (LGALS3, LYZ2, CTSD), cytoskeletal and cytoskeleton-associated proteins 359 
(CAPG, CORO1C, CNN3, several myosin heavy chain subunits), peroxisomal enzymes 360 
(CAT, HSD17B4, MDH1) and known myelin proteins (PLLP/plasmolipin, CRYAB, 361 
GJB1/CX32). For comparison, the abundance of the marker proteolipid protein (PLP/DM20) 362 
(69) and the periaxin-associated integrin beta-4 (ITGB4) (12) in myelin was unaltered in Prx-/- 363 
myelin. Together, differential proteome analysis finds considerably more proteins and protein 364 
groups to be altered in Prx-/- myelin than previously known (Figure 5C, D-Dµµµ), probably 365 
reflecting the complex pathology observed in this model (26,64). 366 
 367 
The monocarboxylate transporter MCT1/SLC16A1 expressed by myelinating 368 
oligodendrocytes (70,71) and Schwann cells (28,72) has been proposed to supply lactate or 369 
other glucose breakdown products to axons, in which they may serve as substrate for the 370 
mitochondrial production of ATP (73±75). In this respect it was striking to find the abundance 371 
of MCT1 significantly reduced in peripheral myelin when PRX is lacking (Figure 5C), a result 372 
that we were able to confirm by immunoblotting (Figure 5E) and immunolabeling of teased 373 
fiber preparations of sciatic nerves (Figure 5F). Notably, reduced expression of MCT1 in 374 
Slc16a1+/- mice impairs axonal integrity at least in the CNS (70,76). The reduced abundance 375 
of MCT1 thus represents an interesting novel facet of the complex pathology in Prx-/- mice. 376 
Considering that the integrity of peripheral axons may be impaired in Prx-/- mice, we 377 
assessed their quadriceps nerves. Indeed, Prx-/- mice displayed reduced axonal diameters, a 378 
progressively reduced total number of axons and a considerable number of myelin whorls 379 
lacking a visible axon (Figure 6), indicative of impaired axonal integrity (77). Yet we note that 380 
molecular or neuropathological features other than the reduced abundance of MCT1 381 
probably also contribute to the axonopathy in Prx-/- mice.  382 
 383 
Together, gel-free, label free proteome analysis provides a cost- and time-efficient method 384 
that provides an accurate, sensitive tool to gain systematic insight into the protein 385 
composition of healthy peripheral myelin and its alterations in pathological situations. Indeed, 386 
gel-free proteome analysis is particularly powerful and comprehensive compared to 2D-387 
DIGE; the workflow presented here appears readily applicable to other neuropathy models, 388 
thereby promising discovery of relevant novel features of their neuropathology.  389 
 390 
391 
DISCUSSION 392 
 393 
We used gel-free, label-free quantitative mass spectrometry to assess the protein 394 
composition of myelin biochemically purified from the sciatic nerves of wild-type mice, 395 
thereby establishing a straightforward and readily applicable workflow to approach the 396 
peripheral myelin proteome. The key to comprehensiveness was to combine the strengths of 397 
three data acquisition modes, i.e., MSE for correct quantification of high-abundant proteins, 398 
UDMSE for deep quantitative proteome coverage including low-abundant proteins and DRE-399 
UDMSE for differential analysis. We suggest that DRE-UDMSE provides a good compromise 400 
between dynamic range, identification rate and instrument run time for routine differential 401 
myelin proteome profiling as a prerequisite for a molecular understanding of myelin 402 
(patho)biology. We have also integrated the resulting compendium with RNA-Seq-based 403 
mRNA abundance profiles in peripheral nerves and neuropathy disease loci. Beyond 404 
providing the largest peripheral myelin proteome dataset thus far, the workflow is appropriate 405 
to serve as starting point for assessing relevant variations of myelin protein composition, e.g., 406 
in different nerves, ages, species and in pathological conditions. The identification of 407 
numerous pathological alterations of myelin protein composition in the Prx-/- neuropathy 408 
model indicates that the method is well suited to assess such diversity.  409 
 410 
Aiming to understand nervous system function at the molecular level, multiple µomicsµ-scale 411 
projects assess the spatio-temporal expression profiles of all mRNAs and proteins in the 412 
CNS including oligodendrocytes and myelin (35±39). Yet, peripheral nerves are also 413 
essential for normal sensory and motor capabilities. Prior approaches to the molecular 414 
profiles of Schwann cells and PNS myelin thus far, however, were performed >8 years ago 415 
(32±34,41,78±80), and the techniques have considerably advanced since. For example, 416 
current gel-free, label-free mass spectrometry can simultaneously identify and quantify the 417 
vast majority of proteins in a sample, thereby providing comprehensive in depth-information. 418 
Moreover, RNA-Seq technology has overcome limitations of the previously used microarrays 419 
for characterizing mRNA abundance profiles with respect to the number of represented 420 
genes and the suitability of the oligonucleotide probes. The present compendium thus 421 
provides high confidence with respect to the identification of myelin proteins, their relative 422 
abundance and their developmental mRNA expression profiles. This view is supported by the 423 
finding that over 80% of the total myelin proteome is constituted by approximately 50 424 
previously known myelin proteins. We believe that the majority of the other identified proteins 425 
represent low-abundant myelin-associated constituents in line with the high efficiency of 426 
biochemical myelin purification. Doubtless, however, the myelin proteome also comprises 427 
contaminants from other cellular sources, underscoring the need of independent validation 428 
for establishing newly identified constituents as true myelin proteins. 429 
 430 
Do myelin proteins exist that escape identification by standard proteomic approaches? 431 
Indeed, some proteins display atypically distributed lysine and arginine residues, which 432 
represent the cleavage sites of the commonly used protease trypsin. The tryptic digest of 433 
these proteins leads to peptides that are not well suited for chromatographic separation 434 
and/or mass spectrometric detection/sequencing, as exemplified by the small hydrophobic 435 
tetraspan-transmembrane myelin proteins MAL (81) and PMP22 (82). We can thus not 436 
exclude that additional proteins with atypical tryptic digest patterns exist in peripheral myelin, 437 
which would need to be addressed by the use of alternative proteases. Moreover, potent 438 
signaling molecules including erbB receptor tyrosine kinases (83,84) and G-protein coupled 439 
receptors (GPRs) (85±87) display exceptionally low abundance. Such proteins may be 440 
identified when applying less stringent identification criteria, e.g., by requiring the sequencing 441 
of only one unique peptide per protein. However, lower stringency would also result in 442 
identifying false-positive proteins, which we wished to avoid for the purpose of the present 443 
compendium. We note that a truly comprehensive spatio-temporally resolved myelin 444 
proteome should preferentially also include systematic information about protein isoforms 445 
and post-translational modifications, which still poses technical challenges.  446 
 447 
Mutations affecting the periaxin (PRX) gene in humans cause CMT type 4F (65,88±90); the 448 
neuropathology resulting from mutations affecting periaxin has been mainly investigated in 449 
the Prx-/- mouse model. Indeed, Prx-/- mice display a progressive peripheral neuropathy 450 
including axon/myelin-units with abnormal myelin thickness, demyelination, tomaculae, onion 451 
bulbs, reduced nerve conduction velocity (64), reduced abundance and mislocalization of the 452 
periaxin-associated DRP2 (9) and reduced internode length (26). Absence of SLIs (64) and 453 
bands of Cajal (26) imply that the non-compact myelin compartments are impaired when 454 
PRX is lacking. In the differential analysis of myelin purified from Prx-/- and control mice we 455 
find that the previously reported reduced abundance of DRP2 (9) represents one of the 456 
strongest molecular changes in the myelin proteome when PRX is lacking. Notably, the 457 
reported morphological changes in this neuropathy model (9,26,64) go along with alterations 458 
affecting the abundance of multiple other myelin-associated proteins, including junctional, 459 
cytoskeletal, extracellular matrix and immune-related proteins as well as lipid-modifying 460 
enzymes. Thus, the neuropathology in Prx-/- mice at the molecular level is more complex 461 
than previously anticipated. It is striking that the abundance of the monocarboxylate 462 
transporter MCT1/SLC16A1 that may contribute to the metabolic supply of lactate from 463 
myelinating cells to axons (27±31) is strongly reduced in Prx-/- myelin. Considering that 464 
MCT1 in Schwann cells mainly localizes to Schmidt Lanterman incisures (SLI) (28) and that 465 
SLI are largely absent from myelin when PRX is lacking (64), the reduced abundance of 466 
MCT1 in Prx-/- myelin may be a consequence of the impaired myelin ultrastructure. Yet, 467 
considering that SLI are part of the cytosolic channels that may represent transport routes 468 
toward Schwann cell-dependent metabolic support of myelinated axons, the diminishment of 469 
MCT1 may contribute to reduced axonal diameters or axonal loss in Prx-/- mice, probably in 470 
conjunction with other molecular or morphological defects. Together, the in depth-analysis of 471 
proteins altered in neuropathy models can contribute to an improved understanding of nerve 472 
pathophysiology.  473 
 474 
Compared to a previous approach (41), the number of proven neuropathy genes of which the 475 
encoded protein is mass spectrometrically identified in peripheral myelin has increased four-476 
fold from eight to 32 in the present study. This reflects both that the number of proteins 477 
identified in myelin has approximately doubled and that more neuropathy genes are known 478 
due to the common use of genome sequencing. We note that our compendium comprises 479 
not only myelin-associated proteins causing (when mutated) demyelinating CMT1 (e.g., 480 
MPZ/P0, NEFL, PMP2) or intermediate CMT4 (GDAP1, NDRG1, PRX) but also axonal 481 
CMT2 (RAB7, GARS, HSPB1). Yet, the expression of genes causative of CMT2 is not 482 
necessarily limited to neurons, as exemplified by the classical myelin protein MPZ/P0. 483 
Indeed, a subset of MPZ-mutations causes axonal CMT2I or CMT2J (91±95), probably 484 
reflecting impaired axonal integrity as consequence of a mutation primarily affecting 485 
Schwann cells. We also note that the nuclear EGR2/KROX20 causative of demyelinating 486 
CMT1D has not been mass spectrometrically identified in myelin, reflecting that Schwann cell 487 
nuclei are efficiently removed during myelin purification.  488 
 489 
While morphological analysis of peripheral nerves by light and electron microscopy is routine 490 
in numerous laboratories, systematic molecular analysis has been less straightforward. 491 
Using the sciatic nerve as a model, we show that systematic assessment of the myelin 492 
proteome and the total nerve transcriptome are suited to determine comprehensive 493 
molecular profiles in healthy nerves and in myelin-related disorders. Myelin proteome 494 
analysis can thus complement transcriptome analysis in assessing development, function 495 
and pathophysiology of peripheral nerves.  496 
497 
MATERIALS AND METHODS 498 
 499 
Mouse models 500 
Prx-/- mice (64) were kept on c57Bl/6 background in the animal facility of the University of 501 
Edinburgh (United Kingdom). Genotyping was by PCR on genomic DNA using the forward 502 
primers 5µ-CAGATTTGCT CTGCCCAAGT and 5µ-CGCCTTCTAT CGCCTTCTTGAC in 503 
combination with reverse primer 5µ-ATGCCCTCAC CCACTAACAG. The PCR yielded a 0.5 504 
kb fragment for the wildtype allele and a 0.75 kb product for the mutant allele. The age of 505 
experimental animals is given in the figure legends. All animal work conformed to United 506 
Kingdom legislation (Scientific Procedures) Act 1986 and to the University of Edinburgh 507 
Ethical Review Committee policy; Home Office project license No. P0F4A25E9. 508 
 509 
Myelin purification  510 
A light-weight membrane fraction enriched for myelin was purified from sciatic nerves of mice 511 
by sucrose density centrifugation and osmotic shocks as described (41,52). Myelin 512 
accumulates at the interface between 0.29 and 0.85 M sucrose. Prx-/- and wild type control 513 
C57Bl/6 mice were sacrificed by cervical dislocation at postnatal day 21 (P21). For each 514 
genotype, myelin was purified as three biological replicates (n=3); each biological replicate 515 
representing a pool of 20 sciatic nerves dissected from 10 mice. Protein concentration was 516 
determined using the DC Protein Assay Kit (Bio-Rad).  517 
 518 
Filter-aided sample preparation for proteome analysis 519 
Protein fractions corresponding to 10 ȝg myelin protein were dissolved and processed 520 
according to a filter-aided sample preparation (FASP) protocol essentially as previously 521 
described for synaptic protein fractions (96) and as adapted to CNS myelin (52,97). Unless 522 
stated otherwise, all steps were automated on a liquid-handling workstation equipped with a 523 
vacuum manifold (Freedom EVO 150, Tecan) by using an adaptor device constructed in-524 
house. Briefly, myelin protein samples were lysed and reduced in lysis buffer (7 M urea, 2 M 525 
thiourea, 10 mM DTT, 0.1 M Tris pH 8.5) containing 1% ASB-14 by shaking for 30 min at 526 
37°C. Subsequently, the sample was diluted with ~10 volumes lysis buffer containing 2% 527 
CHAPS to reduce the ASB-14 concentration and loaded on centrifugal filter units (30 kDa 528 
MWCO, Merck Millipore). After removal of the detergents by washing twice with wash buffer 529 
(8 M urea, 10 mM DTT, 0.1 M Tris pH 8.5), proteins were alkylated with 50 mM 530 
iodoacetamide in 8 M urea, 0.1 M Tris pH 8.5 (20 min at RT), followed by two washes with 531 
wash buffer to remove excess reagent. Buffer was exchanged by washing three times with 532 
50 mM ammonium bicarbonate (ABC) containing 10 % acetonitrile. After three additional 533 
washes with 50 mM ABC/10% acetonitrile, which were performed by centrifugation to ensure 534 
quantitative removal of liquids potentially remaining underneath the ultrafiltration membrane, 535 
proteins were digested overnight at 37°C with 400 ng trypsin in 40 µl of the same buffer. 536 
Tryptic peptides were recovered by centrifugation followed by two additional extraction steps 537 
with 40 µl of 50 mM ABC and 40 µl of 1% trifluoroacetic acid (TFA), respectively. Aliquots of 538 
the combined flow-throughs were spiked with 10 fmol/ȝl of \east enolase-1 tryptic digest 539 
standard (Waters Corporation) for quantification purposes and directly subjected to analysis 540 
by liquid chromatography coupled to electrospray mass spectrometry (LC-MS). A pool of all 541 
samples was injected at least before and after any sample set to monitor stability of 542 
instrument performance. 543 
 544 
Mass spectrometry 545 
Nanoscale reversed-phase UPLC separation of tryptic peptides was performed with a 546 
nanoAcquit\ UPLC s\stem equipped with a S\mmetr\ C18 5 ȝm, 180 ȝm î 20 mm trap 547 
column and a HSS T3 C18 1.8 ȝm, 75 ȝm î 250 mm anal\tical column (Waters Corporation) 548 
maintained at 45°C. Injected peptides were trapped for 4 min at a flow rate of 8 µl/min 0.1% 549 
TFA and then separated over 120 min at a flow rate of 300 nl/min with a gradient comprising 550 
two linear steps of 3-35% mobile phase B in 105 min and 35-60% mobile phase B in 15 min, 551 
respectively. Mobile phase A was water containing 0.1% formic acid while mobile phase B 552 
was acetonitrile containing 0.1% formic acid. Mass spectrometric analysis of tryptic peptides 553 
was performed using a Synapt G2-S quadrupole time-of-flight mass spectrometer equipped 554 
with ion mobility option (Waters Corporation). Positive ions in the mass range m/z 50 to 2000 555 
were acquired with a typical resolution of at least 20.000 FWHM (full width at half maximum) 556 
and data were lock mass corrected post-acquisition. UDMSE and DRE-UDMSE analyses 557 
were performed in the ion mobility-enhanced data-independent acquisition mode with drift 558 
time-specific collision energies as described in detail by Distler et al. (48,49). Specifically, for 559 
DRE-UDMSE a deflection device (DRE lens) localized between the quadrupole and the ion 560 
mobility cell of the mass spectrometer was cycled between full (100% for 0.4 sec) and 561 
reduced (5% for 0.4 sec) ion transmission during one 0.8 sec full scan. Continuum LC-MS 562 
data were processed for signal detection, peak picking, and isotope and charge state 563 
deconvolution using Waters ProteinLynx Global Server (PLGS) version 3.0.2 (47). For 564 
protein identification, a custom database was compiled by adding the sequence information 565 
for yeast enolase 1 and porcine trypsin to the UniProtKB/Swiss-Prot mouse proteome and by 566 
appending the reversed sequence of each entry to enable the determination of false 567 
discovery rate (FDR). Precursor and fragment ion mass tolerances were automatically 568 
determined by PLGS 3.0.2 and were typically below 5 ppm for precursor ions and below 10 569 
ppm (root mean square) for fragment ions. Carbamidomethylation of cysteine was specified 570 
as fixed and oxidation of methionine as variable modification. One missed trypsin cleavage 571 
was allowed. Minimal ion matching requirements were two fragments per peptide, five 572 
fragments per protein, and one peptide per protein. The FDR for protein identification was set 573 
to 1% threshold. 574 
 575 
Analysis of proteomic data  576 
For each genotype (Prx-/- and wild type control mice sacrificed at P21), biochemical fractions 577 
enriched for PNS myelin were analyzed as three biological replicates (n=3 per condition); 578 
each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. The 579 
samples were processed with replicate digestion and injection, resulting in four technical 580 
replicates per biological replicate and thus a total of 12 LC-MS runs per condition to be 581 
compared, essentially as previously reported for CNS myelin (36,97). The freely available 582 
software ISOQuant (www.isoquant.net) was used for post-identification analysis including 583 
retention time alignment, exact mass and retention time (EMRT) and ion mobility clustering, 584 
peak intensity normalization, isoform/homology filtering and calculation of absolute in-sample 585 
amounts for each detected protein (48,49,98) according to the TOP3 quantification approach 586 
(53,54). Only peptides with a minimum length of seven amino acids that were identified with 587 
scores above or equal to 5.5 in at least two runs were considered. FDR for both peptides and 588 
proteins was set to 1% threshold and only proteins reported by at least two peptides (one of 589 
which unique) were quantified using the TOP3 method. The parts per million (ppm) 590 
abundance values (i.e. the relative amount (w/w) of each protein in respect to the sum over 591 
all detected proteins) were log2-transformed and normalized by subtraction of the median 592 
derived from all data points for the given protein. Significant changes in protein abundance 593 
were detected by moderated t-statistics essentially as described (96,97) across all technical 594 
replicates using an empirical Bayes approach and false discovery (FDR)-based correction for 595 
multiple comparisons (100). For this purpose, the Bioconductor R packages "limma" (101) 596 
and "q-value" (102) were used in RStudio, an integrated development environment for the 597 
open source programming language R. Proteins identified as contaminants (e.g. components 598 
of blood or hair cells) were removed from the analysis. Proteins with ppm values below 100 599 
which were not identified in one genotype were considered as just above detection level and 600 
also removed from the analysis. The relative abundance of a protein in myelin was accepted 601 
as altered if both statistically significant (q-value <0.05). Pie charts, heatmaps and volcano 602 
plots were prepared in Microsoft Excel 2013 and GraphPad Prism 7. Pearson¶s correlation 603 
coefficients derived from log2-transformed ppm abundance values were clustered and 604 
visualized with the tool heatmap.2 contained in the R package gplots (CRAN.R-605 
project.org/package=gplots). Only pairwise complete observations were considered to 606 
reduce the influence of missing values on clustering behavior. The mass spectrometry 607 
proteomics data have been deposited to the ProteomeXchange Consortium 608 
(proteomecentral.proteomexchange.org) via the PRIDE partner repository (103) with the 609 
dataset identifier PXD015960. 610 
 611 
Gel electrophoresis and silver staining of gels 612 
Protein concentration was determined using the DC Protein Assay kit (BioRad). Samples 613 
were separated on a 12% SDS-PAGE for 1 h at 200 V using the BioRad system, fixated 614 
overnight in 10% [v/v] acetic acid and 40 % [v/v] ethanol and then washed in 30% ethanol (2x 615 
20 min) and ddH2O (1x 20 min). For sensitization, gels were incubated 1 min in 0.012% [v/v] 616 
Na2S2O3 and subsequently washed with ddH2O (3x 20 sec). For silver staining, gels were 617 
impregnated for 20 min in 0.2 % [w/v] AgNO3 / 0.04% formaldehyde, washed with ddH2O (3x 618 
20 sec) and developed in 3% [w/v] Na2CO3 / 0.02% [w/v] formaldehyde. The reaction was 619 
stopped by exchanging the solution with 5% [v/v] acetic acid. 620 
 621 
Immunoblotting 622 
Immunoblotting was performed as described (104,105). Primary antibodies were specific for 623 
dystrophin-related-protein 2 (DRP2; Sigma; 1:1000), peripheral myelin protein 2 (PMP2; 624 
ProteinTech Group 12717-1-AP; 1:1000), proteolipid protein (PLP/DM20; A431 (106); 625 
1:5000), Monocarboxylate transporter 1 (MCT1/SLC16A1; (107); 1:1000), periaxin (PRX; 626 
(59); 1:1000), sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1; 1:2000; 627 
Abcam #13736-1-AP), myelin protein zero (MPZ/P0; (108); kind gift by J. Archelos-Garcia; 628 
1:10.000), voltage-dependent anion-selective channel protein (VDAC; Abcam #ab15895; 629 
1:1000), basigin (BSG/CD147; ProteinTech Group #ab64616; 1:1000), neurofilament H 630 
(NEFH/NF-H; Covance #SMI-32P; 1:1000), voltage-gated potassium channel subunit A 631 
member 1 (KCNA1; Neuromab #73-007; 1:1000), EGR2/KROX20 ((109); kind gift by D. 632 
Meijer, Edinburgh; 1:1000) and myelin basic protein (MBP; 1:2000). To generate the latter 633 
antisera, rabbits were immunized (Pineda Antikörper Service, Berlin, Germany) with the 634 
KLH-coupled peptide CQDENPVVHFFK corresponding to amino acids 212-222 of mouse 635 
MBP isoform 1 (Swisprot/Uniprot-identifier P04370-1). Anti-MBP antisera were purified by 636 
affinity chromatography and extensively tested for specificity by immunoblot analysis of 637 
homogenate of brains dissected from wild-type mice compared to Mbpshiverer/shiverer mice that 638 
lack expression of MBP. Appropriate secondary anti-mouse or -rabbit antibodies conjugated 639 
to HRP were from dianova. Immunoblots were developed using the Enhanced 640 
Chemiluminescence Detection kit (Western Lightning® Plus, Perkin Elmer) and detected with 641 
the Intas ChemoCam system (INTAS Science Imaging Instruments GmbH, Göttingen, 642 
Germany).  643 
 644 
Immunolabelling of teased fibers  645 
Teased fibers were prepared as previously described (9,110). For each genotype, one male 646 
mouse was sacrificed by cervical dislocation at P17. Immunolabelling of teased fibers was 647 
performed as described (69). Briefly, teased fibers were fixed for 5 min in 4% 648 
paraformaldehyde, permeabilized 5 min with ice-cold methanol, washed in PBS (3x 5 min) 649 
and blocked for 1 h at 21°C in blocking buffer (10% horse serum, 0.25% Triton X-100, 1% 650 
bovine serum albumin in PBS). Primary antibodies were applied overnight at 4°C in 651 
incubation buffer (1.5% horse serum, 0.25% Triton X-100 in PBS). Samples were washed in 652 
PBS (3x 5 min) and secondary antibodies were applied in incubation buffer (1 h, RT). 653 
Samples were again washed in PBS (2x 5 min), and 4µ,6-diamidino-2-phenylindole (DAPI; 654 
1:50 000 in PBS) was applied for 10 min at RT. Samples were briefly washed 2x with ddH2O 655 
and mounted using Aqua-Poly/Mount (Polysciences, Eppelheim, Germany). Antibodies were 656 
specific for myelin-associated glycoprotein (MAG clone 513; Chemicon MAB1567; 1:50) and 657 
MCT1/SLC16A1 (107). Secondary antibodies were donkey Į-rabbit-Alexa488 (Invitrogen 658 
A21206; 1:1000) and donkey Į-mouse-Alexa555 (Invitrogen A21202; 1:1000). Labeled 659 
teased fibers were imaged using the confocal microscope Leica SP5. The signal was 660 
collected with the objective HCX PL APO lambda blue 63.0.x1.20. DAPI staining was excited 661 
with 405 nm and collected between 417 nm - 480 nm. To excite the Alexa488 fluorophore an 662 
Argon laser with the excitation of 488 nm was used and the emission was set to 500 nm - 663 
560 nm. Alexa555 was excited by using the DPSS561 laser at an excitation of 561 nm and 664 
the emission was set to 573 nm - 630 nm. To export and process the images LAS AF lite and 665 
Adobe Photoshop were used. 666 
 667 
mRNA abundance profiles 668 
Raw data were previously established (60) from the sciatic nerves of wild type Sprague 669 
Dawley rats at the indicated ages (E21, P6, P18; n=4 per time point). Briefly, sciatic nerves 670 
were dissected, the epineurium was removed, total RNA was extracted with the RNeasy Kit 671 
(Qiagen), concentration and quality (ratio of absorption at 260/280 nm) of RNA samples were 672 
determined using the NanoDrop spectrophotometer (ThermoScientific), integrity of the 673 
extracted RNA was determined with the Agilent 2100 Bioanalyser (Agilent Technologies) and 674 
RNA-Seq was performed using the Illumina HiSeq2000 platform. RNA-Seq raw data are 675 
available under the GEO accession number GSE115930 (60). For the present analysis, the 676 
fastqfiles were mapped to rattus norvegicus rn6 using Tophat Aligner and then quantified 677 
based on the Ensemble Transcripts release v96. The raw read counts were then normalized 678 
using the R package DESeq2. The normalized gene expression data was then standardized 679 
to a mean of zero and a standard deviation of one, therefore genes with similar changes in 680 
expression are close in the euclidian space. Clustering was performed on the standardized 681 
data using the R package mfuzz. Transcripts displaying abundance differences of less than 682 
10% coefficient of variation were considered developmentally unchanged. 683 
 684 
Venn diagrams 685 
Area-proportional Venn diagrams were prepared using BioVenn (111) at www.biovenn.nl/. 686 
 687 
GO-term 688 
For functional categorization of the myelin proteome the associated gene ontology terms 689 
were systematically analyzed on the mRNA abundance cluster using the Database for 690 
Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov). For 691 
comparison known myelin proteins according to literature were added. 692 
 693 
Histological analysis 694 
Prx-/- and control mice were perfused at the indicated ages intravascularly with fixative 695 
solution (2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M sodium cacodylate buffer, pH 696 
7.4). Quadriceps nerves were removed, fixed for 2 h at room temperature, followed by 18 h 697 
at 4°C in the same fixative, postfixed in OsO4, dehydrated a graded series of ethanol, 698 
followed by propylene oxide and embedded in Araldite. All axons not associated with a 699 
Remak bundle were counted and categorized as myelinated or non-myelinated. All myelin 700 
profiles lacking a recognizable axon were counted. The total number of axons were counted 701 
on micrographs of toluidine blue stained Araldite sections (0.5 µm) of quadriceps nerves. 702 
Precise p-values for the quantitative comparison between Ctrl and Prx-/- mice were: Total 703 
number of axons (Figure 6B; Student¶s unpaired t-test): 2 mo p=0.01734; 4 mo p=2.1E-05; 9 704 
mo p=0.007625; Number of myelinated axons (Figure 6C; Student¶s unpaired t-test): 2 mo 705 
p=0.00444; 4 mo p=2.12E-05; 9 mo p=0.005766; Number of empty myelin profiles (Figure 706 
6D; Student¶s unpaired t-test): 2 mo p=0.004445; 4 mo p=0.001461; 9 mo p=0.000695; 707 
Axonal diameters (Figure 6E-G; two-sided Kolmogorow-Smirnow test): 2 mo p=2.20E-16; 4 708 
mo p=2.20E-16; 9 mo p=2.20E-16.  709 
 710 
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FIGURE LEGENDS 1108 
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 1110 
Figure 1. Proteome analysis of peripheral myelin 1111 
(A) Schematic illustration of a previous approach to the peripheral myelin proteome (41) 1112 
compared with the present workflow. Note that the current workflow allows largely automated 1113 
sample processing and omits labor-intense 2-dimensional differential gel-electrophoresis, 1114 
thereby considerably reducing hands-on time. Nano LC-MS analysis by data-independent 1115 
acquisition (DIA) using three different data acquisition modes provides efficient identification 1116 
and quantification of abundant myelin proteins (MSE; see Figure 2), a comprehensive 1117 
inventory (UDMSE; see Figures 3-4) and gel-free differential analysis of hundreds of distinct 1118 
proteins (DRE-UDMSE; see Figure 5). Samples were analyzed in three biological replicates.  1119 
(B) Immunoblot of myelin biochemically enriched from sciatic nerves of wild-type mice at 1120 
postnatal day 21 (P21). Equal amounts of corresponding nerve lysate were loaded to 1121 
compare the abundance of marker proteins for compact myelin (MPZ/P0, MBP, PMP2), non-1122 
compact myelin (PRX), the Schwann cell nucleus (KROX20/EGR2), axons (NEFH, KCNA1) 1123 
and mitochondria (VDAC). Blots show n=2 biological replicates representative of n=3 1124 
biological replicates. Note that myelin markers are enriched in purified myelin; other cellular 1125 
markers are reduced.  1126 
(C) Number and relative abundance of proteins identified in myelin purified from the sciatic 1127 
nerves of wild-type mice using three different data acquisition modes (MSE, UDMSE, DRE-1128 
UDMSE). Note that MSE (orange) provides the best information about the relative abundance 1129 
of high-abundant myelin proteins (dynamic range of more than four orders of magnitude) but 1130 
identifies comparatively fewer proteins in purified myelin. UDMSE (blue) identifies the largest 1131 
number of proteins but provides only a lower dynamic range of about three orders of 1132 
magnitude. DRE-UDMSE (green) identifies an intermediate number of proteins with an 1133 
intermediate dynamic range of about four orders of magnitude. Note that MSE with very high 1134 
dynamic range is required for the quantification of the exceptionally abundant myelin protein 1135 
zero (MPZ/P0), myelin basic protein (MBP) and periaxin (PRX). ppm, parts per million. 1136 
(D) Venn diagram comparing the number of proteins identified in PNS myelin by MSE, 1137 
UDMSE and DRE-UDMSE. Note the high overlap of identified proteins.  1138 
(E) Venn diagram of the proteins identified in PNS myelin by UDMSE in this study compared 1139 
with those identified in two previous approaches (41,42).  1140 
 1141 
 1142 
Figure 1-VXSSlemeQW 1. ClXVWeUed heaWmaS Rf PeaUVRQ¶V cRUUelaWiRQ cRefficieQWV for 1143 
protein abundance comparing data acquisition modes. 1144 
The heatmap compares the log2 transformed ppm protein abundance values to assess 1145 
peripheral myelin purified from wild type mice using three data acquisition modes (MSE, 1146 
UDMSE, DRE-UDMSE). The inset shows the color key and the histogram for the values of the 1147 
correlation coefficients. Note that the runs cluster with a high overall correlation (>0.75) into 1148 
three conditions defined by the acquisition mode, in agreement with the experimental design. 1149 
Among the samples analyzed by different acquisition modes, DRE-UDMSE similarly 1150 
correlates with both MSE and UDMSE, reflecting its intermediate nature.  1151 
 1152 
 1153 
Figure 2. Relative abundance of peripheral myelin proteins 1154 
MSE was used to identify and quantify proteins in myelin purified from the sciatic nerves of 1155 
wild-type mice at P21; their relative abundance is given as percent with relative standard 1156 
deviation (% +/- RSD). Note that known myelin proteins constitute >80% of the total myelin 1157 
protein; proteins not previously associated with myelin constitute <20%. Mass spectrometric 1158 
quantification based on 3 biological replicates per genotype with 4 technical replicates each 1159 
(see Figure 1-source data 1).  1160 
 1161 
 1162 
Figure 3. Developmental mRNA abundance profiles of myelin-associated genes 1163 
(A) K-means clustering was performed for the mRNA profiles of those 1046 proteins in our 1164 
myelin proteome inventory for which significant mRNA expression was found by RNA-Seq in 1165 
the sciatic nerve of rats dissected at ages E21, P6, P18 and 6 months (M6). Note that this 1166 
filtering strategy allows to selectively display the developmental abundance profiles of those 1167 
transcripts that encode myelin-associated proteins rather than of all transcripts present in the 1168 
nerve. Standardized mRNA abundance profiles are shown (n=4 biological replicates per 1169 
age). Known myelin genes are displayed in red. For comparison, Pmp22 mRNA was 1170 
included although the small tetraspan protein PMP22 was not mass spectrometrically 1171 
identified due to its unfavorable distribution of tryptic cleavage sites. Normalized counts for all 1172 
mRNAs including those displaying developmentally unchanged abundance are provided in 1173 
Figure 3-Source data 1.  1174 
(B) Numbers of mRNAs per cluster.  1175 
 1176 
 1177 
Figure 4. Categorization of annotated protein functions 1178 
All proteins identified in peripheral myelin by UDMSE (turquoise) and the respective 1179 
developmental expression clusters (Figure 3; shades of red) were analyzed for 1180 
overrepresented functional annotations using gene ontology (GO) terms. The graph displays 1181 
the percentage of proteins in each cluster that were annotated with a particular function. For 1182 
comparison, known myelin proteins were annotated. n.o., not over-represented.  1183 
 1184 
 1185 
Figure 5. Molecular analysis of myelin in the Prx-/- mouse model of CMT4F 1186 
(A) Myelin purified from sciatic nerves dissected from Prx-/- and control mice at P21 was 1187 
separated by SDS-PAGE (0.5 µg protein load) and proteins were visualized by silver 1188 
staining. Bands constituted by the most abundant myelin proteins (MPZ/P0, MBP, PRX) are 1189 
annotated. Note that no band constituted by PRX was detected in Prx-/- myelin and that 1190 
several other bands also display genotype-dependent differences in intensity. Gel shows n=2 1191 
biological replicates representative of n=3 biological replicates.  1192 
(B) The relative abundance of proteins in myelin purified from Prx-/- sciatic nerves as 1193 
quantified by MSE is given as percent with relative standard deviation (% +/- RSD). Note the 1194 
increased relative abundance of MPZ/P0 and MBP compared to wild-type myelin (see 1195 
Figure 2) when PRX is lacking. Mass spectrometric quantification based on 3 biological 1196 
replicates with 4 technical replicates each (see Figure 5-source data 1). 1197 
(C,D) Differential proteome analysis by DRE-UDMSE of myelin purified from Prx-/- and wild-1198 
type mice. Mass spectrometric quantification based on 3 biological replicates per genotype 1199 
with 4 technical replicates each (see Figure 5-source data 2). (C) Top 40 proteins of which 1200 
the abundance is reduced (blue) or increased (red) in peripheral myelin purified from Prx-/- 1201 
compared to wild-type mice with the highest level of significance according to the -log10 1202 
transformed q-value (green). In the heatmaps, each horizontal line corresponds to the fold-1203 
change (FC) of a distinct protein compared to its average abundance in wild-type myelin 1204 
plotted on a log2 color scale. Heatmaps display 12 replicates, i.e. 3 biological replicates per 1205 
genotype with 4 technical replicates each. (D-Dµµµ) Volcano plots representing genotype-1206 
dependent quantitative myelin proteome analysis. Data points represent quantified proteins 1207 
in Prx-/- compared to wild-type myelin and are plotted as the log2-transformed fold-change 1208 
(FC) on the x-axis against the -log10-transformed q-value on the y-axis. Stippled lines mark a 1209 
-log10-transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1210 
Highlighted are the datapoints representing the Top 10 proteins displaying highest zdist 1211 
values (Euclidean distance between the two points (0,0) and (x,y) with x = log2(FC) and y = -1212 
log10(q-value) (red circles in D), immune-related proteins (purple circles in Dµ), proteins of 1213 
the extracellular matrix (ECM; yellow circles in Dµµ) and known myelin proteins (blue circles in 1214 
Dµµµ). n.d., not detected; n.q., no q-value computable due to protein identification in one 1215 
genotype only. Also see Figure 5-supplement 1. 1216 
(E) Immunoblot of myelin purified from Prx-/- and control sciatic nerves confirms the reduced 1217 
abundance of DRP2, SLC16A1/MCT1, BSG and PMP2 in Prx-/- myelin, as found by 1218 
differential DRE-UDMSE analysis (in Figure 5C,D). PRX was detected as genotype control; 1219 
PLP/DM20 and ATP1A1 serve as markers. Blot shows n=2 biological replicates per 1220 
genotype.  1221 
(F) Teased fiber preparations of sciatic nerves dissected from Prx-/- and control mice 1222 
immunolabelled for MAG (red) and SLC16A1 (green). Note that SLC16A1 co-distributes with 1223 
MAG in Schmidt-Lanterman incisures (SLI) in control but not in Prx-/- nerves, in accordance 1224 
with the reduced abundance of SLC16A1 in Prx-/- myelin (Figure 5C-E). Also note that, in 1225 
Prx-/- myelin, SLI were largely undetectable by MAG immunolabeling.  1226 
 1227 
 1228 
Figure 5-VXSSlemeQW 1. ClXVWeUed heaWmaS Rf PeaUVRQ¶V cRUUelaWiRQ cRefficieQWV fRU 1229 
protein abundance comparing genotypes.  1230 
(A) The heatmap compares the log2 transformed ppm protein abundance values from the 1231 
DRE-UDMSE runs to assess peripheral myelin purified from wild type and Prx-/- mice. The 1232 
inset shows the color key and the histogram for the values of the correlation coefficients. 1233 
Note that the runs cluster with a high overall correlation (>0.85) into two conditions defined 1234 
by the genotype, in agreement with the experimental design.  1235 
(B) Volcano plot representing genotype-dependent quantitative myelin proteome analysis. 1236 
Data points represent quantified proteins in Prx-/- compared to wild-type myelin plotted as the 1237 
log2-transformed fold-change (FC) on the x-axis against the -log10-transformed q-value on 1238 
the y-axis. Note the different axis scale compared to Figure 5D. Stippled line marks a -log10-1239 
transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1240 
Highlighted is the datapoint for PRX to illustrate that only trace amounts of PRX were 1241 
detected when assessing Prx-/- myelin. ATP2A1, ATP1A4 and PLCD1 were not detected in 1242 
Prx-/- myelin. 1243 
 1244 
 1245 
Figure 6. Progressive loss and reduced diameters of peripheral axons in Prx-/- mice 1246 
(A-D) Genotype-dependent quantitative assessment of light micrographs of toluidine-stained 1247 
semi-thin sectioned quadriceps nerve dissected at 2, 4 and 9 months of age reveals 1248 
progressive loss of peripheral axons in Prx-/- compared to control mice.  1249 
(A) Representative micrographs. Arrows point at myelinated axons; asterisk denotes an 1250 
unmyelinated axon; arrowhead points at a myelin whorl lacking a recognizable axon. Scale 1251 
bars, 10 µm.  1252 
(B) Total number of axons per nerve that are not associated with a Remak bundle.  1253 
(C) Total number of myelinated axons per nerve. 1254 
(D) Total number per nerve of myelin whorls that lack a recognizable axon.  1255 
Mean +/ SD, n=3-4 mice per genotype and age; *P<0.05, **P<0.01, ***P<0.001 by Student¶s 1256 
unpaired t-test.  1257 
(E-G) Genotype-dependent assessment of myelinated axons shows a shift toward reduced 1258 
axonal diameters in quadriceps nerves of Prx-/- compared to control mice at 2 months (E), 4 1259 
months (F) and 9 months (G) of age. Data are presented as frequency distribution with 0.5 1260 
µm bin width. ***, p<0.001 by two-sided Kolmogorow-Smirnow test. For precise p-values see 1261 
methods section.  1262 
 1263 
 1264 
Figure 1-source data 1. Label-free quantification of proteins in wild-type PNS myelin 1265 
fractions by three different data acquisition modes 1266 
Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1267 
derived from four technical replicates (replicate digestion and replicate injection) per three 1268 
biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1269 
runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; 7 amino 1270 
acids) were identified by database search against the UniprotKB/SwissProt mouse database 1271 
using PLGS. Data were post-processed with the software package ISOQuant to calculate 1272 
absolute in-sample amounts for each detected protein based on the TOP3 approach. 1273 
Reported abundance values are defined as the relative amount of each protein in respect to 1274 
the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1275 
contaminant proteins like keratins were filtered. 1276 
Æ sheet 1: protein identification details 1277 
Æ sheet 2: WT myelin proteome by MSE  1278 
Æ sheet 3: WT myelin proteome by UD-MSE 1279 
Æ sheet 4: WT myelin proteome by DRE UD-MSE 1280 
Æ sheet 5: 45 proteins additionally identified in WT myelin by 1D-gel-LC-MS 1281 
 1282 
 1283 
Figure 3-source data 1. Normalized developmental mRNA abundance data 1284 
Æ sheet 1: normalized values for all individual 4 biological replicates per age 1285 
Æ sheet 2: normalized values for biological replicates averaged to give mean per age 1286 
 1287 
 1288 
Figure 5-source data 1. Label-free quantification of proteins in PNS myelin fractions 1289 
from Prx-/- mice by MSe 1290 
Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1291 
derived from four technical replicates (replicate digestion and replicate injection) per three 1292 
biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1293 
runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; 7 amino 1294 
acids) were identified by database search against the UniprotKB/SwissProt mouse database 1295 
using PLGS. Data were post-processed with the software package ISOQuant to calculate 1296 
absolute in-sample amounts for each detected protein based on the TOP3 approach. 1297 
Reported abundance values are defined as the relative amount of each protein in respect to 1298 
the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1299 
contaminant proteins like keratins were filtered.  1300 
Æ sheet 1: protein identification details 1301 
Æ sheet 2: Prx-/- myelin proteome by MSE 1302 
 1303 
 1304 
Figure 5-source data 2. Label-free quantification of proteins in PNS myelin fractions 1305 
from WT and Prx-/- mice by DRE-UDMSe 1306 
Identification and quantification data of detected myelin-associated proteins by DRE-UDMSe. 1307 
For each genotype, tryptic peptides derived from four technical replicates (replicate digestion 1308 
and replicate injection) per three biological replicate (20 sciatic nerves pooled from 10 1309 
animals) were analyzed by LC-MS (24 runs in total). Proteins (FDR < 1%; 2 peptides/protein) 1310 
and peptides (FDR < 1%; 7 amino acids) were identified b\ database search against the 1311 
UniprotKB/SwissProt mouse database using PLGS. Data were post-processed with the 1312 
software package ISOQuant to calculate absolute in-sample amounts for each detected 1313 
protein based on the TOP3 approach. Reported abundance values are defined as the 1314 
relative amount of each protein in respect to the sum over all detected proteins (ppm: parts 1315 
per million (w/w) of total protein). Typical contaminant proteins like keratins were filtered. The 1316 
-log10-transformed q-value was plotted against the log2-transformed fold change to obtain 1317 
the volcano plot shown in Figure 5D. As no imputation of missing values was performed, 1318 
proteins exclusive for only one of the conditions do not appear in the volcano plot, but are 1319 
appended at the end of the list. Criteria for statistically significant regulation were as follows: 1320 
fold change of at least 1.5 and q-value below 0.05. 1321 
Æ sheet 1: protein identification details 1322 
Æ sheet 2: comparison of WT vs. Prx-/- myelin proteome by DRE-UDMSE 1323 
 1324 
1325 
 1326 
Protein name Gene Reference TMD Cluster 
     
2-hydroxyacylsphingosine 1-beta-galactosyltransferase Ugt8 Bosio et al., 1996 2 P6-up 
Syntrophin D Snta1 Fuhrmann-Stroissnigg et al., 2012 - P18-up 
Annexin A2 Anxa2 Hayashi et al., 2007 - Descending 
Band 4.1 protein B / 4.1B Epb41l3 Ivanovic et al., 2012 - Descending 
Band 4.1 protein G / 4.1G Epb41l2 Ohno et al., 2006 - P6-up 
Breast carcinoma-amplified sequence 1  Bcas1 Ishimoto et al., 2017 - P6-up 
Cadherin 1/ E-Cadherin Cdh1 Fannon et al., 1995 1 P18-up 
Carbonic anhydrase 2 Ca2 Cammer et al., 1987 - Descending 
Catenin D1 Ctnna1 Murata et al., 2006 - U-shaped 
Catenin ß1 Ctnnb1 Fannon et al., 1995 - Descending 
Caveolin 1 Cav1 Mikol et al., 2002 1 P18-up 
CD9, tetraspanin 29 Cd9 Ishibashi et al., 2004 4 P18-p 
CD59A  Cd59a Funabashi et al., 1994 1 P18-up 
CD47, integrin-associated signal transducer Cd47 Gitik et al., 2011 5 P6-up 
CD81, tetraspanin 28 Cd81 Ishibashi et al., 2004 4 P18-up 
CD82, tetraspanin 27 Cd82 Chernousov et al., 2013 4 P18-up 
CD151, tetraspanin 24 Cd151 Patzig et al., 2011 4 P18-up 
Cell adhesion molecule 4/ NECL4 Cadm4 Spiegel et al., 2007 1 P6-up 
Cell division control protein 42 Cdc42 Benninger et al., 2007 - P6-up 
Cell surface glycoprotein MUC18 Mcam Shi et al., 1998 1 Descending 
Ciliary neurotrophic factor Cntf Rende et al., 1992 - Late-up 
CKLF-like MARVEL TMD-containing 5 Cmtm5 Patzig et al., 2011 4 P6-up 
Claudin-19 Cldn19 Miyamoto et al., 2005 4 P6-up 
Cofilin 1 Cfl1 Sparrow et al., 2012 - Descending 
Crystallin D2 Cryab d'Antonio et al., 2006 - P18-up 
Cyclic nucleotide phosphodiesterase Cnp Matthieu et al., 1980 - P6-up 
SaUcogl\can į Sgcd Cai et al., 2007 1 Late-up 
Dihydropyrimidinase related protein 1 Crmp1 d'Antonio et al., 2006 - Descending 
Disks large homolog 1 Dlg1 Cotter et al., 2010 - Descending 
Dynein light chain 1 Dynll1 Myllykoski et al. 2018 - P6-up 
Dystroglycan Dag1 Yamada et al, 1994 1 P6-up 
Dystrophin/DP116 Dmd Cai et al., 2007 - P6-up 
Dystrophin-related protein 2 Drp2 Sherman et al., 2001 - P18-up 
E3 ubiquitin-protein ligase NEDD4 Nedd4 Liu et al., 2009 - Descending 
Ezrin Ezr Scherer et al., 2001 - P6-up 
Fatty acid synthase Fasn Salles et al., 2002 - P6-up 
Flotillin 1 Flot1 Lee et al., 2014 - P18-up 
Gap junction ß1 protein / Cx32 Gjb1 Li et al., 2002 4 P18-up 
Gap junction Ȗ3 protein / Cx29 Gjc3 Li et al., 2002 1 P6-up 
Gelsolin Gsn Gonçalves et al., 2010 - Late-up 
Glycogen synthase kinase 3ß Gsk3b Ogata et al., 2004 - P6-up 
Integrin D6 Itga6 Nodari et al., 2008 1 P6-up 
Integrin DV Itgav Chernousov & Carey, 2003 1 Descending 
Integrin ß1  Itgb1 Feltri et al., 2002 1 Descending 
Integrin ß4 Itgb4 Quattrini et al., 1996 2 P18-up 
Junctional adhesion molecule C Jam3 Scheiermann et al., 2007 1 P18-up 
Laminin D2 Lama2 Yang et al., 2005 - P6-up 
Laminin D4 Lama4 Yang et al., 2005 - Descending 
Laminin ß1 Lamb1 LeBeau et al., 1994 - Descending 
Laminin ß2 Lamb2 LeBeau et al., 1994 - P18-up 
Laminin Ȗ1 Lamc1 Chen & Strickland, 2003 - Descending 
Membrane Palmitoylated Protein 6 Mpp6 Saitoh et al., 2019 - P6-up 
Microtubule-associated protein 1A Map1a Fuhrmann-Stroissnigg et al., 2012 - P18-up 
Microtubule-associated protein 1B Map1b Fuhrmann-Stroissnigg et al., 2012 - P6-up 
Mitogen-activated protein kinase 1/ ERK2 Mapk1 Mantuano et al., 2015 - Descending 
Mitogen-activated protein kinase 3/ ERK1 Mapk3 Mantuano et al., 2015 - P18-up 
Moesin Msn Scherer et al., 2001 - Unchanged 
Monocarboxylate transporter 1 Slc16a1 Domenech-Estevez et al., 2015 11 P18-up 
Myelin associated glycoprotein Mag Figlewicz et al., 1981 1 P6-up 
Myelin basic protein Mbp Boggs, 2006 - P6-up 
Myelin protein 2 Pmp2 Trapp et al., 1984 - P18-up 
Myelin protein zero/ P0 Mpz Giese et al., 1992 1 P6-up 
Myelin proteolipid protein Plp1 Garbern et al., 1997 4 P6-up 
Myotubularin-related protein 2 Mtmr2 Bolino et al., 2004 - P6-up 
Noncompact myelin-associated protein Ncmap Ryu et al., 2008 1 P18-up 
NDRG1, N-myc downstream regulated Ndrg1 Berger et al., 2004 - P18-uP 
Neurofascin Nfasc Tait et al., 2000 2 P18-up 
Nidogen 1 Nid1 Lee et al., 2007 - Descending 
P2X purinoceptor 7 P2rx7 Faroni et al., 2014 - P6-up 
Paxillin Pxn Fernandez-Valle et al., 2002 - P6-up 
Periaxin Prx Gillespie et al., 1994 - P6-up 
Plasmolipin Pllp Bosse et al., 2003 4 P18-up 
Profilin 1 Pfn1 Montani et al., 2014 - Descending 
Lin-7 homolog C Lin7c Saitoh et al., 2017 - P6-up 
Rac1 Rac1 Benninger et al., 2007 - U-Shaped 
Radixin Rdx Scherer et al., 2001 - Descending 
RhoA Rhoa Brancolini et al., 1999 - U-Shaped 
Septin 2 Sept 2 Buser et al., 2009 - Descending 
Septin 7 Sept 7 Buser et al., 2009 - U-Shaped 
Septin 8 Sept 8 Patzig et al., 2011 - P18-up 
Septin 9 Sept 9 Patzig et al., 2011 - P6-up 
Septin 11 Sept 11 Buser et al., 2009 - Descending 
Sirtuin 2, NAD-dependent deacetylase Sirt2 Werner et al., 2007 - P18-up 
Spectrin alpha chain, non-erythrocytic 1 Sptan1 Susuki et al., 2018 - P18-up 
Spectrin beta chain, non-erythrocytic 1 Sptbn1 Susuki et al., 2018 - P18-up 
Tight junction protein ZO-1 Tjp1 Poliak et al., 2007 - P6-up 
Tight junction protein ZO-2 Tjp2 Poliak et al., 2007 - P6-up 
Transferrin Tf Liu et al., 1990 2 Late-up 
Vimentin Vim Triolo et al., 2012 - Unchanged  
Vinculin Vcl Beppu et al., 2015 - Descending 
Table 1. Known myelin proteins in the myelin proteome. Proteins mass-spectrometrically identified in peripheral myelin 1327 
are compiled according to availability of prior references as myelin proteins. Given are the official gene name, one selected 1328 
reference, the number of transmembrane domains (TMD) and the mRNA abundance profile cluster (see Figure 3).  1329 
 1330 
1331 
 1332 
Protein name Gene name OMIM# Gene Locus Neuropathy 
Monoacylglycerol lipase ABHD12 ABHD12 613599 20p11.21 PHARC 
Apoptosis-inducing factor 1  AIFM1 300169 Xq26.1 CMTX4, DFNX5 
Na+/K+ -transporting ATPase D ATP1A1 182310 1p13.1 CMT2DD 
Cytochrome c oxidase subunit 6A1  COX6A1 602072 12q24.31 CMTRID 
Dystrophin-related protein 2 DRP2 300052 Xq22.1   CMTX 
Dynactin subunit 1 DCTN1 601143 2p13.1 DHMN7B 
Dynamin 2 DNM2 602378 19p13.2 CMT2M, CMTDIB 
Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 600112 14q32.31 CMT20, SMALED1 
E3 SUMO-protein ligase EGR2 129010 10q21.3 CMT1D, CMT3, CMT4E 
Glycine-tRNA ligase GARS (Gart) 600287 7p14.3 CMT2D, HMN5A 
Gap junction ß1 protein / Cx32 GJB1 304040 Xq13.1 CMTX1 
Guanine nucleotide-binding protein ß4 GNB4 610863 3q26.33 CMTDIF 
Histidine triad nucleotide-binding protein 1 HINT1 601314 5q23.3 NMAN 
Hexokinase 1 HK1 142600 10q22.1 CMT4G 
Heat shock protein ß1 HSPB1 602195 7q11.23 CMT2F, DHMN2B 
Kinesin heavy chain isoform 5A KIF5A 602821 12q13.3 SPG10 
Prelamin A/C LMNA 150330 1q22 CMT2B1 
Neprilysin MME 120520 3q25.2 CMT2T, SCA43 
Myelin protein zero/ P0 
 
 
MPZ 
 
 
159440 
 
 
1q23.3 
 
 
CHN2,CMT1B, CMT2I, 
CMT2J,CMT3, CMTDID, 
Roussy-Levy syndrome 
Myotubularin-related protein 2 MTMR2 603557 11q21 CMT4B1 
Alpha-N-acetylglucosaminidase NAGLU (NAGA) 609701 17q21.2 CMT2V 
NDRG1, N-myc downstream regulated NDRG1 605262 8q24.22 CMT4D 
Neurofilament heavy polypeptide NEFH 162230 22q12.2 CMT2CC 
Neurofilament light polypeptide NEFL 162280 8p21.2 CMT2E, CMT1F, CMTDIG 
Peripheral myelin protein 2 PMP2 170715 8q21.13 CMT1G 
Peripheral myelin protein 22 
 
 
PMP22 
 
 
601907 
 
 
17p12 
 
 
CMT1A, CMT1E, CMT3, 
HNPP,  
Roussy-Levy syndrome 
Ribose-phosphate pyrophosphokinase 1 
 
PRPS1 
 
311850 
 
Xq22.3 
 
Arts syndrome, CMTX5, 
DFNX1 
Periaxin PRX 605725 19q13.2 CMT4F, CMT3 
Ras-related protein Rab 7a RAB7A 602298 3q21.3 CMT2B 
Septin 9 SEPT9 604061 17q25.3 HNA 
Transitional ER-ATPase VCP 601023 9p13.3 CMT2Y 
Tryptophan-tRNA ligase, cytoplasmic WARS 191050 14q32.32 HMN9 
Tyrosine-tRNA ligase, cytoplasmic YARS 603623 1p35.1 DI-CMTC 
Table 2. Peripheral myelin proteins identified in PNS myelin involved in neuropathological diseases. Proteins 1333 
massspectrometically identified in peripheral myelin were analyzed regarding the involvement of the ortholog human gene 1334 
in neuropathological diseases. PMP22 was added, though it was not identified by MS analyses due to its unfavorable 1335 
distribution of tryptic cleavage sites. CMT, Charcot-Marie-Tooth disease; DHMN, distal hereditary motor neuropathy; DI-1336 
CMTC, dominant intermediate CMTC; DFN, X-linked deafness; HMN, hereditary motor neuropathy; HSAN, hereditary 1337 
sensory and autonomic neuropathy; HNA, hereditary sensory and autonomic neuropathy; OMIM, Online Mendelian 1338 
Inheritance in Man; PHARC, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract; SCA, spinocerebellar 1339 
ataxia; SPG, spastic paraplegia. 1340 
 1341 
